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Abstract 
As part of a program investigating cyclic peptides with an internal aromatic hydrophobic scaffold as 
potential novel anti-bacterial agents, we explored the synthesis of simple tyrosine-based systems. 
These were prepared via key intermediates containing internal allylglycine and allyltyrosine 
residues for subsequent ring closing metathesis reactions. Although the resulting anti-bacterial 
activity against Staphylococcus aureus was modest, this represents a novel and simple route to this 
class of compounds. One intermediate acyclic dipeptide precursor showed good activity against S. 
aureus with an MIC of 7.8 µg/mL. 
 
1. Introduction 
The need for new, novel anti-bacterial agents is becoming increasingly important with the 
escalating number of cases of multi-drug resistant bacterial infections being reported.
1,2
 A number 
of compounds targeting these resistant strains have recently been reported, e.g. linezolid,
3
 however, 
resistance to these new molecules has already started to emerge.
4-6
 Vancomycin has long been cast 
as the drug-of-last-resort and has been in use for a number of years, despite the increasing 
prevalence of VRE (vancomycin resistant Enterococci)
7
 and now vancomycin resistant 
Staphylococcus aureus.
8
 The complicated ring systems of vancomycin limits investigations into 
extensive structure-activity relationships based on the parent structure. Therefore, we instigated a 
programme investigating the synthesis of potential anti-bacterial agents using some structural 
elements of vancomycin, but dramatically simplifying the hydrophobic scaffold to simple moieties 
that hold a tripeptide in a defined conformation. Thus far, we have reported cyclic peptides 









 with numerous derivatives showing significant anti-bacterial activity (Figure 
1). We report here the synthesis and anti-bacterial activity against S. aureus of an additional, 
simpler hydrophobic scaffold based on a phenyl unit, exemplified by the cyclic tripeptide 4, 




























































































2. Results and Discussion 
Our target structure is typified by the cyclic peptide 11 (Scheme 1), the hydrochloride salt of 4 (R = 
Lys or Arg side chains). The tripeptide precursor of 11 features a key protected terminal amino 
group-containing amino acid (Lys; in later work this was replaced by an Arg residue with a 
protected guanidino moiety) and an allyltyrosine which provides two roles: the aromatic moiety 
serves as the hydrophobic unit and the olefin enables the cyclisation to be undertaken via a reliable 
ring-closing metathesis (RCM) reaction
14
 with the third unit of the tripeptide, an allylglycine unit. 
The modular synthetic strategy also allows for the rapid generation of analogues including 
variations in the amino acid configuration (R or S) as well as variations in the amino acid side-
chains themselves, e.g. the RCM of two incorporated allyltyrosine units.  
 
The synthesis of 11 was realized (Scheme 1) in a six-step sequence starting with commercially 
available L-allylglycine 5. The acid 5 was esterified
15
 using thionyl chloride in a solution of 
anhydrous methanol at 0 
o
C, to give 6 in quantitative yield. The synthesis of the dipeptide 7 used 
typical EDCI/HOBt peptide coupling conditions
16
 reacting 6 with commercially available Fmoc-D-
Lys(Boc)-OH and resulted in a 94% yield of 7 after column chromatography. Removal of the base 
labile Fmoc group from the dipeptide 7 was achieved using standard conditions
17
 of a 1% 







































R = Fmoc, 7
R = H,       8
R = Boc,    10











Scheme 1: Synthesis of Cyclic Peptides: a) MeOH, SOCl2, 0 °C-RT, 16 h, 100%. b) Fmoc-D-
Lys(Boc)-OH, EDCI, HOBt, DIPEA, DMF, 0 °C-RT, 16 h, 94%. c) 1% piperidine/CH3CN, RT, 3 
h, 99%. d) 14, EDCI, HOBt, DMF, 0 °C-RT, 16 h, 69%. e) Grubbs [Ru] catalyst, benzylidene 
bis(tricyclohexylphosphine)dichlororuthenium, CH2Cl2, ∆, 48 h, 75%. f) i) TFA/ CH2Cl2 (1:1); ii) 
1M HCl/ether, RT, 3 h, 49%. 
 
We next required the N-protected allyltyrosine 14 which was generated by treating commercially 
available ethyl (2S)-2-acetamido-3-(4-hydroxyphenyl)propanoate 12 with K2CO3 and then 
allylbromide to produce the L-O-allyl-tyrosine derivative 13 in quantitative yield with no further 
purification required (Scheme 2). The ethyl ester of 13 was hydrolysed by reaction with 2 
equivalents of LiOH in 3:1 THF-H2O and afforded, after acidification, the free carboxylic acid 16 in 
quantitative yield (Scheme 2). The corresponding D-analogue of 14 was also required for the 
generation of analogues, but this required a slightly modified synthetic strategy based upon the 
commercial availability of compounds (Scheme 3). Therefore, the acid catalysed esterification of D-
tyrosine 15 with thionyl chloride in methanol yielded the methyl ester 16 in quantitative yield as the 
ammonium salt which was then treated with 5 M sodium acetate at 0 
o
C to produce the free amine. 
Acetic anhydride was added to the aqueous solution and the N-acetyl derivative 17 precipitated in 
76% yield. The last two steps of the synthesis were performed in the same manner as described for 

















Scheme 2: Synthesis of L-N-acetyl-O-allyltyrosine: a) allyl bromide, DMF, K2CO3, RT, 16 h, 













R = H,    (D)-15 a R = H,    (D)-19
R = Me, (D)-18 d(R)-17
 
Scheme 3: Synthesis of D-N-acetyl-O-allyltyrosine: a) MeOH, SOCl2, 0 °C-RT, 16 h, 100%. b) 
Ac2O, NaOAc, 0 °C, 76%. c) allyl bromide, DMF, K2CO3, RT 16 h, 85%. d) LiOH, THF/H2O, RT, 
16 h, 88%. 
 
The coupling of the α-amino dipeptide 8 to the allyltyrosine 14 (Scheme 8) used standard 
EDCI/HOBt peptide coupling conditions to yield 9 in 69% yield after purification by column 
chromatography. A ring closing metathesis (RCM) reaction of the peptide 9 with Grubbs′ first 
generation catalyst (benzylidene bis(tricyclohexylphosphene)dichlororuthenium) gave 10 as a 
mixture of E and Z isomers in 75% yield, which could not be separated. The E:Z ratio and alkene 
coupling constants could not be determined by analysis of the 
1
H NMR spectra due to overlapping 
peaks, but all the spectroscopic data was consistent with the cyclic structure 10. Subsequent Boc 
deprotection of 10 with TFA and anion exchange by treatment with HCl/ether followed by 
precipitation gave the amine hydrochloride salt 11 in 49% yield.  
 
This modular approach to novel cyclic peptide synthesis allowed for the rapid generation of 
analogues to probe structure-activity relationships (SARs) upon testing for anti-bacterial activity. 
Therefore, we synthesised and tested a series of analogues that included: 
a) Variations in the stereochemistry at C2 (D- and L-allylGly), C5 (D- and L-amino acids) and 
C8 (D- and L-allyltyrosine). 
b) Variations in the C5 amino acid including the N-terminal side chains of Lys, Arg and N-
guanidylLys. 
c) Some of the N-deprotected acyclic di- and tripeptide intermediates synthesised. 
5 






























































































































































































































































































Scheme 4: ‘X’ in structures represents the amino acid side chain as defined under ‘C5’ in the 
associated tables. a) MeOH, SOCl2, 0 °C-RT, 16 h. b) Fmoc-D or L-Lys(Boc)-OH, EDCI, HOBt, 
DIPEA, DMF, 0 °C-RT, 16 h. c) 1% pip/CH3CN, RT, 3 h. d) 14 or 19, EDCI, HOBt, DMF, 0 °C-
RT, 16 h. e) Grubb [Ru] catalyst - benzylidene bis(tricyclohexylphosphine)dichlororuthenium, 
CH2Cl2, ∆, 48 h. f) i. TFA/ CH2Cl2 (1:1) ii. 1M HCl/ether, RT, 3 h, 49%. 
6 
While not exhaustively producing all possible variations defined above, a selection of target 
compounds were synthesised using the same synthetic strategy as outlined in Scheme 1. Scheme 4 
shows the generation of deprotected cyclic tyrosine-based molecules 11 and 44 – 49. Schemes 5 and 
6 summarise the deprotection of the intermediate di- and tripeptides respectively that were also 
tested for anti-bacterial activity. The acyclic N-guanidineLys derivatives 62 and 63 were also N-
deprotected (Scheme 7) to allow for biological testing as their hydrochloride salts and the 
corresponding cyclic tyrosine versions of these derivatives were more conveniently synthesised 




























































Scheme 5: Synthesis of the deprotected acyclic dipeptide derivatives. a) i) TFA/CH2Cl2, (1:1), ii. 
1M HCl/ether, RT, 3 h. ‘X’ in structures represents the amino acid side chain as defined under ‘C5’ 





































































































Scheme 6: Synthesis of the deprotected acyclic tripepetide derivatives. a) i) TFA/CH2Cl2, (1:1), ii. 
1M HCl/ether, RT, 3 h. ‘X’ in structures represents the amino acid side chain as defined under ‘C5’ 












































































Scheme 7: Synthesis of the deprotected acyclic tripeptide derivatives containing the guanidated 
lysine amino acid side chain. a) i. TFA, CH2Cl2 (1:1); ii. Tf-N=C(NHBoc)2, Et3N, RT, 16 h. b) i) 
TFA/CH2Cl2, (1:1), ii. 1M HCl/ether, RT, 3 h. ‘X’ in structures represents the amino acid side chain 















































Scheme 8: Synthesis of the cyclic tripeptide containing the guanidated lysine amino acid side chain. 
a) i. TFA/CH2Cl2 (1:1), ii) Tf-N=C(NHBoc)2, Et3N, RT,16 h. b) i. TFA/CH2Cl2, (1:1), ii. 1M 
HCl/ether, RT, 3 h, 87% (2 steps). 
 
 
The synthesis of the cyclic tripeptides containing two tyrosine residues is outlined in Scheme 9. 
This necessitated access to the ester protected allyltyrosine 69 which was generated analogously to 
those established in the synthesis of the tyrosines 14 and 19 (Schemes 2 and 3). The completion of 
the synthesis of the cyclic dityrosine derivatives also used standard conditions as indicated in 
Scheme 9. Some acyclic tyrosine dipeptides 70 - 82 were also generated to supplement SAR studies 


























































67 68 69 70
R = H,    75
R = Boc, 74
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Scheme 9: a) i) MeOH, SOCl2, 0 °C-RT, 16 h; ii) (Boc)2O, DMF, RT; 16% (2 steps) b) allyl 
bromide, DMF, K2CO3, RT 16 h, 76%. c) TFA/CH2Cl2 (1:1) ii. 1 M HCl/ether, RT, 3 h, 100% d) 
Fmoc-D-Lys(Boc)-OH, EDCI, HOBt, DIPEA, DMF, 0 °C-RT, 16 h, 75%. e) 1% pip/CH3CN, RT, 3 
h, 97%. f) 14, EDCI, HOBt, DMF, 0 °C-RT, 16 h, 37%. g) Grubbs [Ru] catalyst - benzylidene 
bis(tricyclohexylphosphine)dichlororuthenium, CH2Cl2, ∆, 48 h, 41%. h) i. TFA/CH2Cl2 (1:1) ii. 

































































Scheme 10: Synthesis of the L-allyltyrosine dipeptide derivatives: a) Fmoc-D- or L-Lys(Boc)-OH 
or Fmoc-D- or L-Arg(PMC)-OH, EDCI, HOBt, DIPEA,  DMF, 0 °C-RT, 16 h. b) i. TFA/CH2Cl2 
(1:1) ii. 1M HCl/ether, RT, 3 h. ‘X’ in structures represents the amino acid side chain as defined 
under ‘C5’ in tables. 
 
9 
3. Anti-bacterial Testing Results 
The anti-bacterial activity results against S. aureus ATCC6538P (Figure 2) were measured as 
minimum inhibitory concentration (MIC), the lowest concentration of compound necessary to 
prevent bacterial growth. The activities ranged from an MIC of 7.8 µg/mL for compound 81 to an 
MIC >125 µg/mL (inactive) for a number of compounds. Vancomycin was used as the 
standard/control and typically had an MIC range of 1.25-2.5 µg/mL.  
 
The most active cyclic compound tested was the dityrosine peptide 75, which had a moderate 
activity of 15.6 µg/mL. As expected, the D-lysine cyclic peptide 11, which is conformationally 
similar to the binaphthyl lead compound 1 (Figure 1), had moderate activity (MIC 62.5 µg/mL) and 
was the most active of the mono-tyrosine compounds. The D-arginine and D-lysine cyclic peptides 
(45 and 11 respectively) had the same activity indicating no advantage in arginine over lysine as the 
basic residue, although the lack of activity with the presence of the homoarginine sidechains 
suggests an optimum chain length for antibacterial activity. Generally the presence of a C-terminal 
residue L-amino acid residue and an adjacent D-amino acid with a basic residue gives rise to better 
activity, e.g 49 versus 45 versus 48. 
 
The greatest activity was found, unexpectedly, with the dipeptide intermediate 81 which was as 
active as the binaphthyl lead compound 1 with an MIC of 7.8 µg/mL. This can be attributed to the 
Fmoc group acting as a hydrophobic scaffold, in a similar manner to the binaphthyl moiety of 1. As 
the molecule also contains a protonated sidechain it meets our previously established criteria for 
antibacterial activity. This compound also has the minimal structural features consistent with the 
anti-staphylococcal pharmacophore proposed for short cationic peptides
18
 The other dipeptide 
analogues featuring O-allyltyrosine (79, 80 and 82) as the C-terminal residue instead of C2-
allylglycine (50-53) also resulted in promising antibacterial activity (MIC 15.6-31.5 µg/mL). The 
allylglycine analogues, with either the D- or L-configuration, all showed poor anti-bacterial activity 
(MIC of 125 µg/mL) significantly less active than the corresponding O-allyltyrosine compounds 
Indicating that some form of hydrophobic moiety is required at the C-terminal end. The tripeptide 
acyclic intermediates failed to produce any significant anti-bacterial activity. 
 
The location of the O-allyltyrosine residue at the C-terminus is more favourable than a C2-
allylglycine residue (e.g. 81 vs 51) suggesting that a hydrophobic entity is required for optimum 
activity at this end of the molecule. The acyclic dipeptides also show a preference for arginine over 
lysine basic side chains. These smaller dipeptides have a degree of conformational freedom and it is 








































































































































































































MIC µg/mL = 125 MIC µg/mL = 15.6
(E/Z)
 
Figure 2: Minimum inhibitory concentration (MIC) data for the anti-bacterial testing of the acyclic 
di- and tripeptides and the cyclic tripeptide derivatives synthesisied. 
 
The third major observation was the hydrophobicity of the molecules. The tyrosine derivative 81, 
which mimics the binaphthyl in the lead compound 1, is significantly smaller and less hydrophobic 
than the scaffold/template of the lead 1. The Fmoc fluorenyl ring system (e.g. in 81) is more 
11 
hydrophobic than a tyrosine residue and more isosteric with the binaphthyl ring system of the lead 
compound. It is clear that the presence of the more hydrophobic Fmoc group increases the activity 
of the compounds in relation to the tyrosine derivative. 
 
4. Conclusions 
We have synthesised a series cyclic peptides based upon allyltyrosine and allylglycine moieties. 
The key cyclisation was achieved via a ring closing metathesis reaction. The anti-bacterial activity 
of the cyclic peptides and their acyclic precursors revealed that for optimum activity: 
 The compounds do not have to be macrocyclic, but can be straight chain peptides. 
 The D-Configuration is preferred for the basic residue, and arginine is preferable over 
lysine. Also, the side chain in homoarginine is too long and renders the compounds inactive. 
 The L-configuration is preferred for the C-terminal amino acid residue. 
 A small hydrophobic group is required near the C-terminus whereas a larger hydrophobic 




Melting point determinations were carried out on a Gallenkamp melting point apparatus. Chemical 
ionization (CI) and electron impact (EI) mass spectra were obtained on a Shimadzu QP-5000 mass 
spectrometer by a direct insertion technique with an electron beam energy of 70 eV. Electrospray 
(ESI) mass spectra were obtained on a VG Autospec spectrometer. High-resolution mass spectra 
(HRMS) were determined on a micromass QTof2 spectrometer using polyethylene glycol or 
polypropylene glycol as the internal standard. The m/z values are stated with their peak intensity as 
a percentage in parentheses. Optical rotations were measured using a Jasco polarimeter with a 10 
mm path length. Proton and carbon nuclear magnetic resonance (NMR) spectra were obtained as 
specified on a Varian Mercury 300 MHz or Varian Inova 500 MHz spectrometer. Spectra were 
recorded in the specified deuterated solvent, and referenced to the residual non-deuterated solvent 
signal. Chemical shifts (δ) in ppm were measured relative to the internal standard. Where samples 
exhibited (E) and (Z) isomers the chemical shifts are separated by (/). In general, the two forms 
could not be separated by flash chromatography. Analytical thin layer chromatography (TLC) was 
carried out on Merck silica gel 60 F254 pre-coated aluminium plates with a thickness of 0.2 mm. All 
column chromatography was performed under ‘flash’ conditions on Merck silica gel 60 (230-400 
mesh). Chromatography solvent mixtures were measured by volume. Organic solvent extracts were 
dried with anhydrous magnesium sulfate. All compounds were judged to be of greater than 95% 
purity based upon 
1
H NMR and TLC analysis. The Grubbs ruthenium catalyst used was specifically 
12 
benzylidene bis(tricyclohexylphosphine) dichlororuthenium. Other general experimental procedures 
have been reported previously.
11 
 
Proton and carbon NMR spectra for all compounds were assigned using the numbering systems as 
illustrated in Figure 3. Cyclic peptoids were named using the IUPAC “superatom” convention, in 






























Figure 3: ‘Superatom’ convention for the numbering of macrocycles.
19 
 
5.2. General Synthetic Procedures 
5.2.1. N-Boc and Pmc Deprotection (Procedure A) 
The N-Boc or Pmc protected amine (1 equiv.) was stirred for 3 h in 1:1 CH2Cl2/ TFA solution at rt. 
The solvent was removed under reduced pressure, and the residue was re-suspended in a minimal 
volume of methanol. The solution was then treated with an excess of 1M HCl/ diethyl ether solution 
and the solvent again evaporated. The crude product was purified by recrystallization/ precipitation 
from CH2Cl2and/ or MeOH by addition of diethyl ether. 
 
5.2.2. Peptide Coupling (Procedure B) 
To a solution of the acid (1 equiv.) in DMF at rt was added HOBt (1.1 equiv.), EDCI (1 equiv.) and 
the amine (1.2 equiv.). If the amine was a hydrochloride salt, DIPEA (1 equiv.) was also added. The 
mixture was allowed to stir for 16 h before the reaction was quenched with water until precipitation 
occurred. The solid was collected by vacuum filtration, and washed thoroughly with water. The 
amorphous product was dried under vacuum over P2O5 to yield the desired peptide. 
 
5.2.3. N-Fmoc Deprotection (Procedure C) 
The Fmoc protected amine was stirred in 1% piperidine/acetonitrile for 3 h at rt. The solvent was 
removed under reduced pressure and the crude product was purified by flash column 
chromatography (15:1, CH2Cl2/MeOH) to yield the free amine. 
 
13 
5.2.4. Macrocyclization by Olefin Metathesis (Procedure D) 
To a solution of the precursor tripeptide in CH2Cl2 (to 0.004 M) was added Grubbs ruthenium 
catalyst (15 mol%) and the resulting solution was heated at reflux for 48 h before the solvent was 
removed by evaporation and the product isolated by flash column chromatography (15:1, 
CH2Cl2/MeOH) to yield the corresponding macrocycle. 
 
5.3. Synthesis of Allylated Tyrosine Amino Acids 
5.3.1. Ethyl (2S)-2-acetamido-3-(4-allyloxyphenyl)propanoate (13) 
To a solution of ethyl (2S)-2-acetamido-3-(4-hydroxyphenyl) propanoate 
monohydrate 12 (2.69 g, 9.98 mmol) and anhydrous K2CO3 (2.75 g, 20.0 mmol) in 
DMF (15 mL) was added allyl bromide (2.42 g, 19.96 mmol). The resulting 
mixture was allowed to stir for 16 h under nitrogen before the reaction was 
quenched with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The 
combined extracts were washed with water (5 x 50 mL), dried and the solvent was evaporated to 
yield the title compound (2.91 g, 9.98 mmol, 100%) as a white solid, which had spectral data in 




 +23.1 (c. 0.1, EtOH).
20




5.3.2. (2S)-2-Acetamido-3-(4-allyloxyphenyl)propanoic acid (14) 
To a solution of 13 (2.90 g, 9.98 mmol) in THF/water, (3:1, 80 mL) was added 
lithium hydroxide monohydrate (838 mg, 20.0 mmol) and the resulting 
suspension was allowed to stir for 16 h. The reaction mixture was diluted with 
water (30 mL) and the THF was removed by evaporation. The aqueous layer was 
extracted with CH2Cl2 (40 mL) to remove unreacted starting material. The aqueous phase was 
acidified with 10% HCl and the resulting precipitate was extracted with CH2Cl2 (3 x 40 mL). The 
combined extracts were dried and evaporated to yield the title compound (2.62 g, 9.98 mmol, 
100%) as white needles, which had spectral data in agreement with that reported.
20














5.3.3. Methyl (2R)-2-amino-(4-hydroxyphenyl)-2-propanoate hydrochloride (16) 
To a solution of (2R)-2-amino-3-(4-hydroxyphenyl)propanoic acid 15 (1.07 g, 5.9 
mmol) in anhydrous MeOH (10 mL) at 0 °C was added dropwise thionyl chloride (2 
mL). The resulting mixture was allowed to stir for 16 h before the solvent was 
removed by evaporation to yield the title compound (1.36 g, 5.9 mmol, 100%) as a 




 -27.7 (c. 0.1, EtOH). 
(lit. [α]D
24
 -27.1 (c. 2.0, MeOH))
21




5.3.4. Methyl (2R)-2-acetamido-3-(4-hydroxyphenyl)propanoate (17) 
A solution of the HCl salt 16 (1.09 g, 6.02 mmol) in water (3 mL) was cooled to 0 
°C before the addition of 5 M sodium acetate solution (35 mL) and a small amount 
of ice. Acetic anhydride (10 mL) was added and the resulting precipitate was 
collected by vacuum filtration and dried to yield the title compound (1.09 g, 4.58 





(c. 0.1, EtOH) (lit. [α]D
25
 -26.6 (c. 0.1, MeOH)
21




5.3.5. Methyl (2R)-2-acetamido-3-(4-allyloxyphenyl)propanoate (18) 
To a solution of 17 (989 mg, 4.17 mmol), and anhydrous K2CO3 (1.15 g, 8.34 
mmol) in DMF (10 mL) was added allyl bromide (1.01 g, 8.34 mmol) and the 
resulting mixture was allowed to stir for 16 h under a nitrogen atmosphere. The 
reaction was quenched with water (30 mL), extracted with ethyl acetate (3 x 30 
mL), and the combined organics were washed with water (5 x 20 mL) before 
drying. The solvent was evaporated to yield the title compound (985 mg, 3.56 mmol, 85%) as a pale 
yellow solid. [α]D
25
 -24.2 (c. 0.1, EtOH). Mp 90 °C. 
1
H NMR (CDCl3, 300 MHz): δ 6.97 (d, J = 8.7 
Hz, 2H, ArH2′ and ArH6′); 6.80 (d, J = 8.7 Hz, 2H, ArH3′ and ArH5′); 6.09 (d, J = 7.8 Hz, 1H, 















1H, H3b′′); 4.83 – 4.77 (m, 1H, H2); 4.47 (d, J = 5.5 Hz, 2H, H1′′); 3.68 (s, 3H, OCH3); 3.08 – 2.94 
(m, 2H, H3); 1.99 (s, 3H, NCOCH3). 
13
C NMR (CDCl3, 75 MHz): δ 172.1, C1; 169.6, NCO; 157.6, 
ArC4′; 133.1, C2′′; 130.1, ArCH2′ and ArCH6′; 127.9, ArC1′; 117.5, C3′′; 114.7, ArCH3′ and 
ArCH5′; 68.6, C1′′; 53.2, C2; 52.2, OCH3; 36.9, C3; 22.9, NCOCH3. MS (CI, +ve) m/z 278 (100%) 
[MH
+
]. HRMS (ESI) calcd for C15H19NO4 277.131408, found 277.130309. 
 
5.3.6. (2R)-2-Acetamido-3-(4-Allyloxyphenyl)propanoic acid (19) 
To a solution of 18 (900 mg, 3.25 mmol) in THF/water, 3:1 (10 mL) was added 
lithium hydroxide monohydrate (273 mg, 6.5 mmol), and the resulting suspension 
was allowed to stir for 16 h. The reaction mixture was diluted with water (30 mL) 
and the THF was removed in vacuo. The aqueous layer was extracted with diethyl 
ether (40 mL) to remove unreacted starting material. The aqueous phase was 
acidified with 10% HCl and the resulting precipitate was extracted with CH2Cl2 (3 x 40 mL). The 
combined CH2Cl2 fractions were dried and concentrated to yield the title compound (750 mg, 2.85 
mmol, 88%) as a white solid. [α]D
23
 -23.2 (c. 0.1, EtOH). Mp 75 °C. 
1
H NMR (D6 acetone, 300 
MHz): δ 7.27 (d, J = 7.8 Hz, 1H, NH); 7.17 (d, J = 8.7 Hz, 2H, ArH2′ and ArH6′); 6.86 (d, J = 8.7 
Hz, 2H, ArH3′and ArH5′); 6.12 – 6.00 (m, 1H, H2′′); 5.40 (dd J = 1.5 Hz, 17.5 Hz, 1H, H3a′′); 5.23 
(dd, J = 1.5, 10.5 Hz, 1H, H3b′′ ); 4.67 (dd, J = 8.1, 10.5 Hz 1H, H2); 4.53 (d, J = 5.1 Hz, 2H, H1′′); 
3.11 (dd, J = 5.4, 14.1 Hz, 1H, 3Ha); 2.93 (dd, J = 8.1, 14.1, 1H, 3Hb); 1.89 (s, 3H, NCOCH3). 
13
C 
NMR (D6 acetone, 75 MHz): δ 173.1, C1; 170.4, NCO; 158.4, ArC4′; 134.8, C2′′; 131.1, ArCH2′ 
and ArCH6′; 130.2, ArC1′; 117.2, C3′′; 115.3, ArCH3′ and ArCH5′; 69.2, C1′′; 54.5, C2; 37.3, C3; 
22.6, NCOCH3. MS (CI, +ve) m/z 264 (100%) [MH
+







5.4. Synthesis of methylester allyl glycines (6 and 21) 
5.4.1. Methyl (2S)-2-amino-4-pentenoate hydrochloride (6) 
To a suspension of (2S)-2-amino-4-pentanoic acid 5 (200 mg, 1.74 mmol) in 
MeOH (6 mL) at 0 °C was added dropwise thionyl chloride (1 mL). The resulting 
solution was allowed to stir for 16 h before the solvent was removed by 
evaporation and the product crystallized with ether. The ether was removed by evaporation to yield 
the title compound (287 mg, 1.74 mmol, 100%) as a white solid, which had spectral data in 
agreement with that reported.
15




5.4.2. Methyl (2R)-2-amino-4-pentenoate hydrochloride (21) 
This was prepared from (2R)-2-amino-4-pentenoic acid (200 mg, 1.74 mmol) in 
methanol (6 mL) using the same procedure as for the synthesis of 6 above, to 
yield the title compound (287 mg, 1.74 mmol, 100%) as a white solid which was 
spectroscopically identical to that reported.
22
 Mp 135-140 °C.  
 
5.5. Synthesis of Protected Dipeptides (7, 22-26) 
5.5.1. Methyl (2S,5R)-2-allyl-3-aza-9-(tert-butoxycarboxamido)-5-(9H-9-
fluorenylmethyloxycarboxamido)-4-oxononanoate (7) 
The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 6 (186 mg, 1.62 
mmol) and (2R)-6-tert-butoxycarboxamido-2-(9H-9-
fluorenylmethyloxycarboxamido)hexanoic acid (633 mg, 1.35 
mmol) to afford 7 (733 mg, 1.27 mmol, 94%) as a cream solid. 
Mp 117-120 °C. 
1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, J = 7.6 
Hz, 2H, ArH1′′ and ArH8′′); 7.59 (d, J = 7.6 Hz, 2H, ArH4′′ and ArH5′′); 7.39 (t, J = 7.6 Hz, 2H, 
ArH3′′
 


























1H, NH); 5.74 – 5.57 (m, 1H, H2′); 5.11 – 5.05 (m, 2H, H3′); 4.70 – 4.62 (m, 2H, H2 and NH); 4.38 
(d, J = 6.7 Hz, 2H, OCH2-H9′′); 4.26 – 4.18 (m, 2H, H5 and H9′′); 3.71 (s, 3H, OCH3); 3.10 (d, J = 
6.3 Hz, 2H, H9); 2.62 – 2.44 (m, 2H, H1′); 1.88 – 1.83 (m, 2H, H8); 1.70 – 1.63 (m, 2H, H7); 1.49 
– 1.37 (m 2H, H7); 1.43 (s, 9H, C(CH3)3). 
13
C NMR (CDCl3, 75 MHz): δ 171.6, C4; 171.2, C1; 
156.0, NCO2; 156.0, NCO2; 143.5, ArC8a′′ and ArC9a′′; 141.1, ArC4a′′ and ArC4b′′; 131.9, C2′; 
127.6, ArCH3′′ and ArCH6′′; 126.9, ArCH2′′ and ArCH7′′; 125.0, ArCH1′′ and ArCH8′′; 119.8, 
C3′; 119.2, ArCH4′′ and ArCH5′′; 79.1, C(CH3)3; 67.1, CH2-C9′′; 54.7, C5; 52.5, OCH3; 51.5, C2; 
47.1, C9′′; 39.8, C9; 36.4, C6; 32.2, C6; 29.7, C8; 28.5, C(CH3)3; 22.4, C7. MS ( ESI, +ve) m/z 
579.9 (80%) [MH
+
], 479.9 (100%) [MH
+





To a solution of 6 (430 mg, 2.61 mmol) and (2S)-6-tert-
butoxycarboxamido-2-(9H-9-fluorenylmethyloxy)carboxamido 
hexanoic acid (1.22 g, 2.61 mmol) in CH2Cl2 (10 mL) was 
added EDCI (500 mg, 2.61 mmol) and a catalytic quantity of 
DMAP. The resulting mixture was allowed to stir at RT for 16 
h. The reaction was diluted with CH2Cl2 (25 mL), then the 
organic layer was washed with brine (2 x 25 mL) and water (2 x 25 mL) and dried, before being 
concentrated. The crude product was purified by flash column chromatography (25:1 CH2Cl2/ 
MeOH) to afford the title compound (1.31 g, 2.27 mmol, 87%) as a cream coloured solid. Mp 123-
126 °C.
 1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, J = 7.6 Hz, 2H, ArH1′′ and ArH8′′); 7.59 (d, J = 7.6 
Hz, 2H, ArH4′′ and ArH5′′); 7.40 (t, J = 7.6 Hz, 2H, ArH3′′ and ArH6′′); 7.31 (ddd, J = 9.0, 7.2, 1.2 
Hz, 2H, ArH2′′ and ArH7′′); 6.46 (bs, 1H, NH); 5.73 – 5.62 (m, 1H, H2′); 5.44 (s, 1H, NH); 5.12 – 

















H9′′); 4.23 – 4.19 (m, 1H, H5); 4.17 (bs, 1H, H9′′); 3.74 (s, 3H, OCH3); 3.16 – 3.05 (m, 2H, H9); 
2.64 – 2.47 (m, 2H, H1′); 1.94 – 1.76 (m, 2H, H7); 1.75 – 1.64 (m, 2H, H6); 1.55 – 1.48 (m 2H, 
H8); 1.44 (s, 9H, C(CH3)3).
 13
C NMR (CDCl3, 75 MHz): δ 171.9, C4; 171.6, C1; 156.2, NCO2; 
143.7, ArC8a′′ and ArC9a′′; 142.7, ArC4a′′ and ArC4b′′; 131.9, C2′; 127.7, ArCH3′′ and ArCH6′′; 
127.0, ArCH2′′ and ArCH7′′; 125.0, ArCH1′′ and ArCH8′′; 119.9, C3′; 119.3, ArCH4′′ and 
ArCH5′′; 79.1, C(CH3)3; 67.0, CH2-C9′′; 54.5, C5; 52.4, OCH3; 50.6, C2; 47.0, C9′′; 39.8, C9; 36.1, 









The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 6 (287 mg, 1.74 
mmol) and (2R)-2-(9H-9-fluorenylmethyloxycarboxamido)-
8-[(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-
chromenylsulfonyl)guanidino]pentanoic acid (961 mg, 1.45 
mmol) to afford 23 (1.01 g, 1.31 mmol, 90%) as a brown 
solid; [α]D
23
 +11.5 (c 0.011, MeOH). IR (neat) νmax 1538, 1445, 1238, 1166, 1109, 736. Mp 96-100 
°C. 
1
H NMR (CDCl3, 300 MHz): δ 7.70 (d, J = 7.5 Hz, 2H, ArH1′′ and ArH8′′); 7.52 (d, J = 7.2 Hz, 
2H, ArH4′′ and ArH5′′); 7.35 (bs, 1H, NH); 7.33 (dd, J = 7.2, 7.2 Hz, 2H, ArH3′′
 
and ArH6′′); 7.20 
(t, J = 7.2 Hz, 2H, ArH2′′ and ArH7′′); 6.35 (s, 2H, NH); 6.26 (bs, 2H, NH); 5.78 – 5.56 (m, 1H, 
H2′); 5.03 (d, J = 18.0 Hz, 1H, H3a′); 4.98 (d, J = 10.2 Hz, 1H, H3b′); 4.53 (dd, J = 7.2, 12.9 Hz, 
1H, H2); 4.27 (d, J = 6.6 Hz, 2H, OCH2-H9′′); 4.17 – 4.02 (m, 2H, H5 and H9′′); 3.63 (s, 3H, 
OCH3); 3.30 – 3.12 (m, 2H, H8); 2.57 (s, 3H, 7′′′-CH3); 2.54 (s, 3H, 5′′′-CH3); 2.50 – 2.47 (m, 4H, 
H1′ and H4′′′); 2.06 (s, 3H, 8′′′-CH3); 1.96 – 1.78 (m, 2H, H7); 1.71 (t, J = 6.6 Hz, 2H, H3
′′′
); 1.66 – 
1.52 (m, 2H, H6); 1.24 (s, 6H, 2 x 2′′′-CH3). 
13

















156.2, ArC6′′′; 153.5, 5-NCO2; 143.6, ArC8a′′′; 143.5, CN3; 141.0, ArC8a′′ and ArC9a′′; 135.3, 
ArC4a′′ and ArC4b′′; 134.7, ArC7′′′; 132.9, ArC5′′′; 132.3, C2′; 127.5, ArCH3′′ and ArCH6′′; 
126.9, ArCH2′′ and ArCH7′′; 125.0, ArCH4′′ and ArCH5′′; 124.0, ArC8′′′; 119.7, ArCH1′′ and 
ArCH8′′; 118.8, C3′; 117.8, ArC4a′′′; 73.6, C2′′′; 67.2, CH2-C9′′; 52.3, C5; 52.0, C2; 52.0, OCH3; 
47.0, C9′′; 40.2, C8; 35.9, C1′; 32.7, C3′′′; 29.8, C6; 26.7, C2′′′-CH3; 25.5, C7; 21.4, C5′′′-CH3; 
18.6, C7′′′-CH3; 17.6, C4′′′; 12.2, C8′′′-CH3. MS (ESI, +ve) m/z 774 (100%) [MH
+
]. HRMS calcd 




The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 6 (287 mg, 1.74 mmol) 
and (2S)-2-(9H-9-fluorenylmethyloxycarboxamido)-8-[(2,2,5,7,8-
pentamethyl-3,4-dihydro-2H-6-chromenylsulfonyl) 
guanidino]pentanoic acid (961 mg, 1.45 mmol) to afford 24 (936 
mg, 1.21 mmol, 83%) as a brown solid; [α]D
23
 +12.1 (c 0.013, MeOH). IR (neat) νmax 1543, 1450, 
1233, 1109, 741. Mp 90-94 °C. Mp 90-94 °C. 
1
H NMR (CDCl3, 300 MHz): δ 7.71 (d, J = 7.5 Hz, 
2H, ArH1′′ and ArH8′′); 7.54 (d, J = 7.0 Hz, 2H, ArH4′′ and ArH5′′); 7.39 (bs, 1H, NH) 7.34 (t, J = 
7.5 Hz, 2H, ArH3′′ and ArH6′′); 7.22 (t, J = 7.5 Hz, 2H, ArH2′′ and ArH7′′); 6.34 (bs, 1H, NH); 
6.12 (d, J = 7.5 Hz 1H, NH); 5.71 – 5.58 (m, 1H, H2′); 5.03 (d, J = 17.0 Hz, 1H, H3a′); 4.98 (d, J = 
10.0 Hz, 1H, H3b′); 4.57 – 4.50 (m, 1H, H2); 4.40 – 4.32 (m, 1H, H5); 4.29 (d, J = 7.2 Hz, 2H, 
OCH2-H9′′); 4.13 – 4.08 (m, 1H, H9′′); 3.65 (s, 3H, OCH3); 3.34 – 3.14 (m, 2H, H8 ); 2.58 (s, 3H, 
7′′′-CH3); 2.55 (s, 3H, 5′′′-CH3); 2.54 – 2.42 (m, 4H, H1′ and H4′′′); 2.07 (s, 3H, 8′′′-CH3); 1.95 – 
1.82 (m, 2H, H6); 1.73 (t, J = 6.5 Hz, 2H, H3′′′); 1.65 – 1.54 (m, 2H, H7); 1.26 (s, 6H, 2 x 2′′′-CH3). 
13
C NMR (CDCl3, 75 MHz): δ 172.0, C4; 171.0, C1; 156.3, ArC6′′′; 153.5, 5-NCO2; 143.6, CN3; 























ArC5′′′; 132.9, C2′; 127.5, ArC3′′ and ArC6′′; 126.9, ArC2′′ and ArC7′′; 125.0, ArC4′′ and ArC5′′; 
124.0, ArC8′′′; 119.8, ArC1′′ and ArC8′′; 118.8, C3′; 117.8, ArC4a; 73.6, C2′′′; 67.2, CH2-C9′′; 
54.1, C5; 52.4, C2; 52.3, OCH3; 47.0, C9′′; 40.5, C8; 35.7, C1′; 32.7, C3′′′; 29.9, C6; 26.8, C2′′′-
CH3; 25.2, C7; 21.4, 5′′′-CH3; 18.6, 7′′′-CH3; 17.6, C4′′′; 12.2, 8′′′-CH3. MS (ESI, +ve) m/z 774 
(20%) [MH
+




The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 21 (287 mg, 1.74 mmol) 
and (2R)-2-(9H-9-fluorenylmethyloxycarboxamido)-8-
[(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonyl) 
guanidino]pentanoic acid (961 mg, 1.45 mmol) to afford 25 (1.01 
g, 1.31 mmol, 90%) as a brown solid; [α]D
23
 +5.3 (c 0.008, 
MeOH). IR (neat) νmax 1724, 1545, 1449, 1236, 1167, 1108, 742. Mp 96-98 °C. 
1
H NMR (CDCl3, 
500 MHz): δ 7.70 (d, J = 7.5 Hz, 2H, ArH1′′ and ArH8′′); 7.53 (d, J = 5.0 Hz, 2H, ArH4′′ and 
ArH5′′); 7.40 (d, J = 4.5 Hz, 1H, NH); 7.34 (t, J = 7.5 Hz, 2H, ArH3′′
 
and ArH6′′); 7.22 (t, J = 7.5 
Hz, 2H, ArH2′′ and ArH7′′); 6.34 (s, 2H, NH); 6.12 (bs, 2H, NH); 5.69 – 5.55 (m, 1H, H2′); 5.03 (d, 
J = 17.0 Hz, 1H, H3a′); 4.98 (d, J = 10.0 Hz, 1H, H3b′); 4.53 (dd, J = 7.2, 12.9 Hz, 1H, H2); 4.36 
(dd, J = 8.5, 12.5 Hz, 1H, H5); 4.29 (d, J = 7.0 Hz, 2H, 9′′-CH2); 4.08 – 4.04 (m, 1H, H9′′); 3.65 (s, 
3H, OCH3); 3.28 – 3.17 (m, 2H, H8); 3.22 (bs, 1H, NH); 2.58 (s, 3H, 7′′′-CH3); 2.55 (s, 3H, 5′′′-
CH3); 2.51 – 2.39 (m, 4H, H1′ and H4′′′); 2.07 (s, 3H, 8′′′-CH3); 1.96 – 1.80 (m, 2H, H7); 1.73 (t, J 
= 6.5 Hz, 2H, H3
′′′
); 1.66 – 1.54 (m, 2H, H6); 1.25 (s, 6H, 2 x 2′′′-CH3). 
13
C NMR (CDCl3, 75 
MHz): δ 172.0, C4; 171.8, C1; 156.2, ArC6′′′; 153.4, 5-NCO2; 143.6, ArC8a′′′; 143.5, CN3; 141.0, 
ArC8a′′ and ArC9a′′; 135.2, ArC4a′′ and ArC4b′′; 134.6, ArC7′′′; 133.0, ArC5′′′; 132.2, C2′; 127.5, 
























119.7, ArCH1′′ and ArCH8′′; 118.6, C3′; 117.8, ArC4a′′′; 73.5, C2′′′; 67.0, 9′′-CH3; 52.3, C5; 52.1, 
C2; 52.2, OCH3; 47.0, C9′′; 40.4, C8; 35.7, C1′; 32.7, C3′′′; 29.8, C6; 26.7, C2′′′-CH3; 25.3, C7; 
21.4, C5′′′-CH3; 18.6, C7′′′-CH3; 17.5, C4′′′; 12.1, C8′′′-CH3. MS (ESI, +ve) m/z 774 (100%) 
[MH
+




The title compound was synthesized using the general peptide 
coupling procedure (Procedure B), from 21 (287 mg, 1.74 mmol) 
and (2S)-2-(9H-9-fluorenylmethyloxycarboxamido)-8-[(2,2,5,7,8-
pentamethyl-3,4-dihydro-2H-6-chromenylsulfonyl) 
guanidino]pentanoic acid (961 mg, 1.45 mmol) to afford 26 (1.00 
g, 1.29 mmol, 89%) as a brown foam; [α]D
23
 +60.2 (c 0.006, MeOH). IR (neat) νmax 1667, 1541, 
1449, 1237, 1166, 1107, 761, 741. Mp 90-92 °C. 
1
H NMR (CDCl3, 300 MHz): δ 7.70 (d, J = 7.6 Hz, 
2H, ArH1′′ and ArH8′′); 7.51 (d, J = 7.6 Hz, 2H, ArH4′′ and ArH5′′); 7.33 (t, J = 7.2 Hz, 2H, ArH3′′ 
and ArH6′′); 7.20 (t, J = 7.2 Hz, 2H, ArH2′′ and ArH7′′); 6.42 (d, J = 7.6 Hz, 1H, NH); 6.34 (s, 1H, 
NH); 6.20 (bs, 1H, NH); 5.60 – 5.69 (m, 1H, H2′); 5.02 (d, J = 18.1 Hz, 1H, H3a′); 4.97 (d, J = 10.5 
Hz, 1H, H3b′); 4.53 (dd, J = 7.6, 13.1 Hz, 1H, H2); 4.26 (d, J = 7.2 Hz, 3H, H5 and 9′′-CH2); 4.06 
(t, J = 7.2 Hz, 1H, H9′′); 3.63 (s, 3H, OCH3); 3.23 (bs, 2H, H8 ); 2.57 (s, 3H, 7′′′-CH3); 2.54 (s, 3H, 
5′′′-CH3); 2.41 – 2.51 (m, 4H, H1′ and H4′′′); 2.07 (s, 3H, 8′′′-CH3); 1.86 – 1.94 (m, 2H, H6); 1.70 
(t, J = 6.7 Hz, 2H, H3′′′); 1.54 – 1.62 (m, 2H, H7); 1.23 (s, 6H, 2 x 2′′′-CH3). 
13
C NMR (CDCl3, 75 
MHz): δ 172.0, C4; 171.8, C1; 156.2, ArC6′′′; 153.2, 5-NCO2; 143.6, CN3; 143.5, ArC8a′′′; 141.0, 
ArC8a′′ and ArC9a′′; 135.3, ArC4a′′ and ArC4b′′; 134.7, ArC7′′′; 133.1, ArC5′′′; 132.3, C2′; 127.5, 
ArC3′′ and ArC6′′; 126.9, ArC2′′ and ArC7′′; 125.0, ArC4′′ and ArC5′′; 123.9, ArC8′′′; 119.7, 
ArC1′′ and ArC8′′; 118.8, C3′; 117.8, ArC4a; 73.5, C2′′′; 67.2, 9′′-CH2; 52.3, C5; 52.2, C2; 51.9, 























CH3; 18.6, 7′′′-CH3; 17.6, C4′′′; 12.1, 8′′′-CH3. MS (ESI, +ve) m/z 774 (12%) [MH
+
], 130 (100%) 
[allylGly]. HRMS calcd for C41H52N5O8S 774.3537, found 774.3536. 
 
5.6. Synthesis of Deprotected Dipeptides (8, 27-31) 
5.6.1. Methyl (2S,5R)-2-allyl-5-amino-3-aza-9-(tert-butoxycarboxamido)-4-oxononanoate (8) 
The title compound was synthesized using the general N-Fmoc deprotection 
procedure (Procedure C), from 7 (715 mg, 1.23 mmol) to yield 8 (436 mg, 
1.22 mmol, 99%) as a cream oil, and was spectroscopically identical to that 





5.6.2. Methyl (2S,5S)-2-allyl-5-amino-3-aza-9-(tert-butoxycarboxamido)-4-oxononanoate (27) 
The title compound was synthesized using the general N-Fmoc deprotection 
procedure (Procedure C), from 22 (1.27 g, 2.19 mmol) to yield 27 (778 mg, 
2.18 mmol, 100%) as a cream oil.
 1
H NMR (CDCl3, 300 MHz): δ 7.81 (d, J 
= 8.0 Hz, 1H, NH); 5.85 – 5.45 (m, 1H, H2′); 5.15 – 5.02 (m, 2H, H3′); 
4.76 (bs, 1H, NH); 4.60 – 4.50 (m, 1H, H2); 3.75 (s, 3H, OCH3); 3.39 (dd, J 
= 4.6, 7.6 Hz, 1H, H5); 3.12 (d, J = 6.3 Hz, 2H, H9); 2.65 – 2.42 (m, 2H, H1′); 1.85 – 1.45 (m, 8H, 
H6, H7, H8 and NH2); 1.44 (s, 9H, C(CH3)3).
 13
C NMR (CDCl3, 75 MHz): δ 174.8, C4; 172.1, C1; 
156.0, NCO2; 132.2, C2′; 118.9, C3′; 78.9, C(CH3)3; 54.8, C5; 52.2, C2; 51.1, OCH3; 40.0, C9; 































The title compound was synthesized using the general N-Fmoc 
deprotection procedure (Procedure C), from 23 (717 mg, 0.93 mmol) 
to yield 28 (407 mg, 0.74 mmol, 80%) as a cream oil, and was 







The title compound was synthesized using the general N-Fmoc 
deprotection procedure (Procedure C), from 24 (749 mg, 0.97 mmol) 
to yield 29 (259 mg, 0.47 mmol, 48%) as a cream oil, [α]D
23
 -12.2 (c 







The title compound was synthesized using the general N-Fmoc 
deprotection procedure (Procedure C), from 25 (693 mg, 0.900 mmol) 
to yield 30 (387 mg, 0.0700 mmol, 78%) as a cream oil.
 1
H NMR 
(CDCl3, 300 MHz): δ 7.87 (d, J = 7.5 Hz, 1H, NH); 6.35 (bs, 3H, 
NH); 5.75 – 5.61 (m, 1H, H2′); 5.09 (d, J = 16.2 Hz, 1H, H3a′); 5.09 
(d, J = 12.0 Hz, 1H, H3b′); 4.56 – 4.50 (m, 1H, H2); 3.72 (s, 3H, OCH3); 3.43 – 3.40 (m 1H, H5); 
3.19 (d, J = 5.4 Hz, 2H, H8); 2.56 (s, 3H, 7′′-CH3); 2.54 (s, 3H, 5′′-CH3); 2.66 – 2.50 (m, 2H, H1′); 























































1.30 (s, 6H, 2 x 2′′-CH3).
 13
C NMR (CDCl3, 75 MHz): δ 175.2, C4; 172.0, C1; 156.1, ArC6′′; 153.4, 
CN3; 135.3, ArC7′′; 134.6, ArC5′′; 133.2, ArC8a′′; 132.2, C2′; 123.9, ArC8′′; 118.9, C3′; 117.8, 
ArC4a; 73.6, C2′′; 54.2, C5; 52.4, OCH3; 51.6, C2; 40.6, C8; 36.2, C1′; 32.8, C4′′; 32.0, C6; 26.8, 
2′′-CH3; 25.3, C7; 21.5, C3′′; 18.6, 5′′-CH3; 17.5, 7′′-CH3; 12.2, 8′′-CH3. MS (ESI, +ve) m/z 552.1 
(40%) [MH
+
], 243.0 (100%) [MH
+ 





The title compound was synthesized using the general N-Fmoc 
deprotection procedure (Procedure C), from 26 (788 mg, 1.01 mmol) 
to yield 31 (552 mg, 1.00 mmol, 99%) as a cream oil; [α]D
23
 +11.6 (c 
0.017, MeOH). IR (neat) νmax 1672, 1543, 1445, 1238, 1166, 1109.
 
1
H NMR (CDCl3, 300 MHz): δ 7.86 (d, J = 7.5 Hz, 1H, NH); 6.33 
(bs, 3H, NH); 5.74 – 5.60 (m, 1H, H2
′
); 5.12 (d, J = 16.8 Hz, 1H, H3a′); 5.11 (d, J = 10.8 Hz, 1H, 
H3b′); 4.53 (dd, J = 7.2, 12.9 Hz, 1H, H2); 3.71 (s, 3H, OCH3); 3.41 (d, J = 7.2 Hz, 1H, H5); 3.23 – 
3.15 (m, 2H, H8); 2.64 – 2.43 (m, 2H, H1′); 2.57 (s, 3H, 7′′-CH3); 2.55 (s, 3H, 5′′-CH3); 2.10 (s, 3H, 
8′′-CH3); 1.82 – 1.71 (m, 4H, H7 and H3′′); 1.63 – 1.52 (m, 2H, H6); 1.30 (s, 6H, 2 x 2′′-CH3).
 13
C 
NMR (CDCl3, 75 MHz): δ 175.2, C4; 172.0, C1; 156.1, ArC6′′; 153.3, CN3; 135.3, ArC7′′; 134.6, 
ArC5′′; 133.2, ArC8a′′; 132.2, C2′; 123.9, ArC8′′; 119.0, C3′; 117.8, ArC4a′′; 73.6, C2′′; 54.2, C5; 
52.3, OCH3; 51.5, C2; 40.7, C8; 36.1, C1′; 32.8, C4′′; 31.9, C6; 26.8, 2′′-CH3; 25.2, C7; 21.5, C3′′; 
18.5, 5′′-CH3; 17.5, 7′′-CH3; 12.2, 8′′-CH3. MS (ESI, +ve) m/z 552.1 (50%) [MH
+
], 162.7 (100%). 






















5.7. Synthesisi of Protected Tripepetides (9, 32 – 37) 
5.7.1. Methyl (2S,5R,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-(4-[tert-
butoxycarboxamido]butyl)-4,7,10-trioxoundecanoate (9) 
The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 8 (440 mg, 1.20 mmol) 
and 14 (270 mg, 1.03 mmol) to afford 9 (424 mg, 0.70 mmol, 69%) 
as a white solid. Mp 149-150 °C. 
1
H NMR (CDCl3, 300 MHz): δ 
7.20 (d, J = 8.0 Hz, 1H, NH); 7.11 (d, J = 8.4 Hz, 2H, ArH2′′′
 
and 
ArH6′′′); 6.84 (d, J = 8.4 Hz, 2H, ArH3′′′ and ArH5′′′); 6.67 (d, J = 
8.0 Hz, 1H, NH); 6.48 (d, J = 7.2 Hz, 1H, NH); 6.10 – 5.96 (m, 1H, 
H2′′′′); 5.72 – 5.61 (m, 1H, H2′); 5.41 (dd, J = 1.3, 17.3 Hz, 1H, H3a′′′′); 5.28 (dd, J = 1.3, 10.5 Hz, 
1H, H3b′′′′); 5.11 – 5.07 (m, 2H, H3′); 4.75 (t, J = 5.9 Hz, 1H, H2); 4.66 – 4.53 (m, 1H, H8); 4.50 
(d, J = 5.5 Hz, 2H, H1′′′′); 4.42 (dd, J = 7.6, 13.1 Hz, 1H, H5); 3.71 (s, 3H, OCH3); 3.06 – 2.96 (m, 
4H, H4′′ and ArCH2); 2.61 – 2.43 (m, 2H, H1′); 1.97 (s, 3H, H11); 1.44 (s, 9H, C(CH3)3); 1.42 – 
1.32 (m, 6H, H1′′,  H2′′ and H3′′).
 13
C NMR (CDCl3, 75 MHz): δ 172.0, C7; 171.1, C1; 170.7, C4; 
170.2, C10; 157.4, NCO2; 155.9, ArC4′′′; 133.0, C2′; 132.3, C2′′′′; 130.1, ArCH2′′′ and ArCH6′′′; 
128.4, ArC1′′′; 118.8, C3′; 117.6, C3′′′′; 114.8, ArCH3′′′ and ArCH5′′′; 79.0, C(CH3)3; 68.8, C1′′′′; 
55.4, C5; 52.8, OCH3; 52.4, C8; 51.8, C2; 40.1, C4′′; 37.5, ArCH2; 36.3, C1′; 31.6, C1′′; 29.7, C3′′; 
28.5, C(CH3)3; 23.1, C11; 22.3, C2′′. MS (ESI, +ve) m/z 603.4 (40%) [MH
+
], 503.4 (100%) [MH
+
 - 

























To a solution of 27 (782 mg, 2.19 mmol) and 14 (576 mg, 2.19 
mmol) in CH2Cl2 (10 mL) was added EDCI (420 mg, 2.19 
mmol) and a catalytic quantity of DMAP. The resulting mixture 
was allowed to stir at RT for 16 h. The reaction was diluted with 
CH2Cl2 (25 mL) and the organic layer was washed with brine (2 
x 25 mL) and water (2 x 25 mL) and dried, before being 
concentrated by evaporation. The crude product was purified by 
flash column chromatography (25:1 CH2Cl2/ MeOH) to afford the title compound (664 mg, 1.10 
mmol, 50%) as a 1:1 mixture of 2 epimers, as a white solid. Mp 112-114 °C. 
1
H NMR (CDCl3, 300 
MHz): δ 7.09 (m, 2H, ArH2′′′ and ArH6′′′); 6.91 (d, J = 8 Hz, 1H, NH); 6.88 – 6.79 (m, 2H, ArH3′′′ 
and ArH5′′′); 6.69 (d, J = 8.0 Hz, 1H, NH); 6.55 (bs, 1H, NH); 6.10 – 5.97 (m, 1H, H1′′′′); 5.77 – 
5.60 (m, 1H, H2′); 5.42 – 5.24 (m, 4H, H3′ and  H3′′′′); 4.96 (bs, 1H, H2); 4.86 (bs, 1H, H8); 4.80 – 
4.60 (m, 2H, H2′′′′); 4.48 (dd, J = 3.0, 8.4 Hz, 1H, H5); 3.74/3.71 (s, 3H, OCH3); 3.12 – 2.92 (m, 
4H, H4′′ and ArCH2); 2.57 – 2.44 (m, 2H, H1′); 1.98/1.96 (s, 3H, H11); 1.79 (s, 2H, H2′′); 1.60 (s, 
2H, H1′′); 1.43 (s, 9H, C(CH3)3); 1.28 (s, 2H, H3′′). 
13
C NMR (CDCl3, 75 MHz): δ 171.8, C7; 
171.7, C1; 171.4/171.2, C4; 170.3, C10; 157.3/157.2, NCO2; 155.9, ArC4′′′; 133.1/133.0, C2′; 
130.2/130.1, ArCH2′′′ and ArCH6′′′; 128.8./128.7, ArC1′′′; 118.6, C3′; 117.5/117.4, C3′′′′; 
114.4/114.3, ArCH3′′′ and ArCH5′′′; 78.6, C(CH3)3; 68.5, C1′′′′; 54.0, C5; 52.4, OCH3; 52.1, C8; 
52.1, C2; 39.9, C4′′; 38.0, ArCH2; 35.8, C1′; 32.7/32.2, C1′′; 29.6/29.3, C3′′; 28.3, C(CH3)3; 
22.9/22.7, C11; 22.3/22.0, C2′′. MS (ESI, +ve) m/z 603.4 (35%) [MH
+
], 503.4 (100%) [MH
+
 (less 

























5.7.3. Methyl (2S,5R,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-([ {2,2,5,7,8-pentamethyl-3,4-
dihydro-2H-6-chromenylsulfonyl}guanidino]propyl)-4,7,10-trioxoundecanoate (33) 
The title compound was synthesised using the general peptide 
coupling procedure (Procedure B) using 28 (387 mg, 0.70 mmol) 
and 14 (153 mg, 0.58 mmol) to afford 33 (336 mg, 0.42 mmol, 73%) 
as a light brown solid. IR (neat) νmax 1653, 1636, 1539, 1508, 1241, 
1107. Mp 172-176 °C. 
1
H NMR (CDCl3, 500 MHz): δ 7.75 (d, J = 
7.5 Hz, 1H, NH); 7.11 (d, J = 8.7 Hz, 2H, ArH2′′′′ and ArH6′′′′); 
6.78 (d, J = 8.4 Hz, 2H, ArH3′′′′ and ArH5′′′′); 6.36 (bs, 2H, NH); 6.18 (bs, 1H, NH); 6.05 – 5.92 
(m, 1H, H2′′′′′); 5.76 – 5.62 (m, 1H, H2′); 5.36 (dd, J = 1.5, 17.4 Hz, 1H, H3a′′′′′); 5.24 (dd, J = 1.5, 
10.5 Hz, 1H, H3b′′′′′); 5.08 (d, J = 15.6 Hz, 1H, H3a′); 5.04 (d, J = 8.4 Hz, 1H, H3b′); 4.52 – 4.44 
(m, 2H, H2 and H5); 4.42 (d, J = 4.8 Hz, 1H, H1′′′′′); 4.38 – 4.28 (m, 1H, H8); 3.69 (s, 3H, OCH3); 
3.14 – 3.00 (m, 2H, H3′′); 3.01 – 2.85 (m, 2H, ArCH2); 2.63 (t, J = 6.9 Hz, 2H, H4′′′); 2.59 (s, 3H, 
7′′′-CH3); 2.57 (s, 3H, 5′′′-CH3); 2.65 – 2.45 (m, 2H, H1′); 2.09 (s, 3H, 8′′′-CH3); 1.93 (s, 3H, H11); 
1.80 (t, J 6.6 Hz, 2H, H3′′′); 1.56 – 1.48 (m, 4H, H1′′ and H2′′); 1.30 (s, 6H, 2 x 2′′′-CH3).
 13
C NMR 
(DMSO, 75 MHz): δ 171.3, C4; 170.9, C1; 171.0, C11; 169.1, C7; 156.5, ArC6′′′; 155.6, ArC8a′′′; 
152.4, CN3; 134.5, ArC7′′′; 133.9, ArC5′′′; 133.3, C2′′′′′; 132.5, C2′; 132.2, ArC4′′′′; 129.5, 
ArCH2′′′′ and ArCH6′′′′; 128.3, ArC8′′′; 122.9, ArC1′′′′; 117.6, ArC4a′′′; 117.0, C3′′′′′; 116.8, C3′; 
113.9, ArCH3′′′′ and ArCH5′′′′; 72.9, C2′′′; 68.0, C′′′′′; 55.1, C2; 51.9, C5; 51.9, OCH3; 51.5, C8; 
40.3, C3′′; 38.6, ArCH2; 36.2, C4′′′; 35.2, C1′; 32.2, C7; 26.2, 2′′′-CH3; 25.1, C6; 22.3, C11; 20.8, 
C3′′′; 18.0, 5′′′-CH3; 16.9, 7′′′-CH3; 11.6, 8′′′-CH3. MS (ESI, +ve) m/z 797 (100%) [MH
+
]. HRMS 




























5.7.4. Methyl (2S,5S,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-([ {2,2,5,7,8-pentamethyl-3,4-
dihydro-2H-6-chromenylsulfonyl}guanidino]propyl)-4,7,10-trioxoundecanoate (34) 
The title compound was synthesized using the general peptide 
coupling procedure (Procedure B), from 29 (236 mg, 0.43 mmol) 
and 14 (95 mg, 0.36 mmol) to afford 34 (207 mg, 0.25 mmol, 72%) 
as a light brown solid. [α]D
24
 +27.8 (c 0.007, MeOH). IR (neat) νmax 
1653, 1541, 1512, 1244, 1109. Mp 99-104 °C. 
1
H NMR (CDCl3, 500 
MHz): δ 7.77 (d, J = 7.8 Hz, 1H, NH); 7.69 (bs, 1H, NH); 7.14 (d, J 
= 7.5 Hz, 1H, NH); 7.04 (d, J = 8.4 Hz, 2H, ArH2′′′′ and ArH6′′′′); 6.74 (d, J = 8.4 Hz, 2H, ArH3′′′′ 
and ArH5′′′′); 6.41 (bs, 2H, NH); 6.05 – 5.92 (m, 1H, H2′′′′′); 5.76 – 5.62 (m, 1H, H2′); 5.37 (dd, J 
= 1.5, 17.4 Hz, 1H, H3a′′′′′); 5.25 (dd, J = 1.5, 10.5 Hz, 1H, H3b′′′′′); 5.07 (d, J = 15.3 Hz, 1H, H3a′); 
5.03 (d, J = 9.3 Hz, 1H, H3b′); 4.78 – 4.71 (m, 1H, H2); 4.64 (bs, 1H, H5); 4.56 (dd, J = 6.9, 13.5 
Hz, 2H, H8); 4.44 (d, J = 5.4 Hz, 2H, H1′′′′′); 3.68 (s, 3H, OCH3); 3.17 (d, J = 4.5 Hz, 2H, H3′′); 
3.17 – 2.79 (m, 2H, ArCH2); 2.59 (t, J = 6.3 Hz, 2H, H4′′′); 2.55 (s, 3H, 7′′′-CH3); 2.53 (s, 3H, 5′′′-
CH3); 2.62 – 2.43 (m, 2H, H1′); 2.08 (s, 3H, 8′′′-CH3); 1.88 (s, 3H, H11); 1.78 (t, J = 6.3 Hz, 2H, 
H3′′′); 1.80 – 1.72 (m, 2H, H7); 1.61 – 1.50 (m, 2H, H6); 1.29 (s, 6H, 2 x 2′′′-CH3).
 13
C NMR 
(CDCl3, 75 MHz): δ 172.0, C4; 171.8, C1; 171.5, C11; 171.0, C7; 157.2, ArC6′′′; 156.2, ArC8a′′′; 
153.4, CN3; 135.2, ArC7′′′; 134.6, ArC5′′′; 133.1, C2′′′′′; 133.1, C2′; 132.3, ArC4′′′; 130.1, 
ArCH2′′′′ and ArCH6′′′′; 128.6, ArC8′′′; 123.9, ArC1′′′′; 118.6, ArC4a′′′; 117.8, C3′′′′′; 117.4, C3′; 
114.5, ArCH3′′′′ and ArCH5′′′′; 73.6, C2′′′; 68.6, C1′′′′′; 60.4, C2; 54.8, C5; 52.3, OCH3; 52.2, C8; 
40.7, C3′′; 37.2, ArCH2; 36.0, C4′′′; 32.8, C1′; 29.7, C7; 26.8, 2′′′-CH3; 25.3, C6; 22.9, C11; 21.5, 
C3′′′; 18.6, 5′′′-CH3; 17.6, 7′′′-CH3; 12.2, 8′′′-CH3. MS (ESI, +ve) m/z 797 (100%) [MH
+
]. HRMS 






























5.7.5. Methyl (2R,5R,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-([ {2,2,5,7,8-pentamethyl-3,4-
dihydro-2H-6-chromenylsulfonyl}guanidino]propyl)-4,7,10-trioxoundecanoate (35) 
The title compound was synthesised using the general peptide 
coupling procedure (Procedure B) using 30 (387 mg, 0.700 mmol) 
and 14 (153 mg, 0.580 mmol) to afford 35 (297 mg, 0.37 mmol, 64%) 
as a light brown solid; [α]D
23
 +0.96 (c 0.011, acetone). IR (neat) νmax 
1645, 1540, 1514, 1245, 1110, 804. Mp 217-220 °C.
 1
H NMR 
(CDCl3, 500 MHz): δ 7.22 (bs, 1H, NH); 7.10 (d, J = 8.0 Hz, 2H, 
ArH2′′′′ and ArH6′′′′); 6.88 (bs, 1H, NH); 6.82 (d, J = 8.5 Hz, 2H, ArH3′′′′ and ArH5′′′′); 6.31 (d, J 
= 7.0 Hz, 1H, NH); 6.17 (bs, 1H, NH); 6.04 – 5.97 (m, 1H, H2′′′′′); 5.73 – 5.65 (m, 1H, H2′); 5.38 
(d, J = 17.0 Hz, 1H, H3a′′′′′); 5.26 (d, J = 10 Hz, 1H, H3b′′′′′); 5.11 (d, J = 17.0 Hz, 1H, H3a′); 5.08 
(d, J = 10.5 Hz, 1H, H3b′); 4.58 – 4.54 (m, 1H, H2); 4.53 – 4.47 (m, 3H, H5 and H1′′′′′); 4.43 (d, J = 
7.5 Hz, 1H, H8); 3.71 (s, 3H, OCH3); 3.15 (bs, 2H, H3′′); 3.04 – 2.97 (m, 2H, ArCH2); 2.63 (t, J = 
6.5 Hz, 2H, H4′′′); 2.59 (s, 3H, 7′′′-CH3); 2.57 (s, 3H, 5′′′-CH3); 2.55 – 2.50 (m, 2H, H1′); 2.11 (s, 
3H, 8′′′-CH3); 1.97 (s, 3H, H11); 1.80 (t, J 6.5 Hz, 2H, H3′′′); 1.58 (s, 6H, 2 x 2′′′-CH3); 1.30 (s, 4H, 
H1′′ and H2′′). 
13
C NMR (DMSO, 75 MHz): δ 171.3, C4; 171.1, C1; 171.0, C11; 169.1, C7; 156.5, 
ArC6′′′; 155.7, ArC8a′′′; 152.1, CN3; 135.4, ArC7′′′; 133.9, ArC5′′′; 133.7, C2′′′′′; 133.3, C2′; 130.0, 
ArC4′′′′; 129.5, ArCH2′′′′ and ArCH6′′′′; 129.4, ArC8′′′; 122.5, ArC1′′′′; 117.8, ArC4a′′′; 117.6, 
C3′′′′′; 117.1, C3′; 114.0, ArCH3′′′′ and ArCH5′′′′; 73.4, C2′′′; 68.0, C′′′′′; 54.4, C2; 51.9, C5; 51.7, 
OCH3; 51.6, C8; 36.9, C3′′; 35.0, ArCH2; 32.1, C4′′′; 29.3, C1′; 26.5, C7; 26.4, 2′′′-CH3; 25.1, C6; 
22.4, C11; 20.8, C3′′′; 18.2, 5′′′-CH3; 17.1, 7′′′-CH3; 12.0, 8′′′-CH3. MS (ESI, +ve) m/z 797.4 
(100%) [MH
+





























5.7.6. Methyl (2R,5S,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-([ {2,2,5,7,8-pentamethyl-
3,4-dihydro-2H-6-chromenylsulfonyl}guanidino]propyl)-4,7,10-trioxoundecanoate (36) 
The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 31 (513 mg, 0.930 mmol) 
and 14 (204 mg, 0.78 mmol) to afford 36 (496 mg, 0.622 mmol, 
80%) as a light brown solid; [α]D
23
 +21.6 (c 0.007, MeOH). IR (neat) 
νmax 1653, 1558, 1541, 1508, 1248, 1109. Mp 98-102 °C. 
1
H NMR 
(CDCl3, 500 MHz): δ 7.71 (d, J = 7.0 Hz, 1H, NH); 7.40 (d, J = 7.0 
Hz, 1H, NH); 7.06 (d, J = 8.5 Hz, 2H, ArH2′′′′ and ArH6′′′′); 6.99 (bs, 1H, NH); 6.76 (d, J = 9.0 Hz, 
2H, ArH3′′′′ and ArH5′′′′); 6.38 (bs, 2H, NH); 6.20 (bs, 1H, NH); 6.05 – 5.98 (m, 1H, H2′′′′′); 5.73 – 
5.65 (m, 1H, H2′); 5.38 (dd, J = 1.5, 17.0 Hz, 1H, H3a′′′′′); 5.25 (dd, J = 1.0, 11.0 Hz, 1H, H3b′′′′′); 
5.09 (d, J = 17.5 Hz, 1H, H3a′); 5.06 (d, J = 10.5 Hz, 1H, H3b′); 4.68 – 4.64 (m, 1H, H2); 4.57 – 
4.52 (m, 2H, H5 and H8); 4.45 (d, J = 5.5 Hz, 2H, H1′′′′′); 3.67 (s, 3H, OCH3); 3.20 (d, J = 4.5 Hz, 
2H, H3′′); 3.13 – 2.81 (m, 2H, ArCH2); 2.61 (t, J = 6.0 Hz, 2H, H4′′′); 2.57 (s, 3H, 7′′′-CH3); 2.55 
(s, 3H, 5′′′-CH3); 2.50 – 2.45 (m, 2H, H1′); 2.09 (s, 3H, 8′′′-CH3); 1.88 (s, 3H, H11); 1.79 (t, J = 7.0 
Hz, 2H, H3′′′); 1.75 – 1.73 (m, 2H, H7); 1.60 – 1.52 (m, 2H, H6); 1.30 (s, 6H, 2 x 2′′′-CH3). 
13
C 
NMR (CDCl3, 75 MHz): δ 172.2, C4; 171.9, C1; 171.3, C11; 170.9, C7; 157.3, ArC6′′′; 156.2, 
ArC8a′′′; 153.5, CN3; 135.3, ArC7′′′; 134.7, ArC5′′′; 133.2, C2′′′′′; 133.1, C2′; 132.4, ArC4′′′; 130.0, 
ArCH2′′′′ and ArCH6′′′′; 128.7, ArC8′′′; 124.0, ArC1′′′′; 118.8, ArC4a′′′; 117.9, C3′′′′′; 117.4, C3′; 
114.1, ArCH3′′′′ and ArCH5′′′′; 73.6, C2′′′; 68.7, C1′′′′′ 55.3, C2; 52.9, C5; 52.3, OCH3; 52.2, C8; 
40.7, C3′′; 37.0, ArCH2; 36.1, C4′′′; 32.8, C1′; 29.3, C7; 26.8, 2′′′-CH3; 25.3, C6; 22.9, C11; 21.5, 
C3′′′; 18.6, 5′′′-CH3; 17.6, 7′′′-CH3; 12.2, 8′′′-CH3. MS (ESI, +ve) m/z 819 (100%) [MNa
+
]. HRMS 
































The title compound was synthesised using the general peptide 
coupling procedure (Procedure B), from 29 (654 mg, 1.19 mmol) 
and 19 (260 mg, 0.99 mmol) to afford 37 (683 mg, 0.86 mmol, 
87%) as a light brown solid. Mp 200-204 °C. 
1
H NMR (CDCl3, 300 
MHz): δ 7.10 (d, J = 8.4 Hz, 2H, ArH2′′′′ and ArH6′′′′); 6.90 (d, J = 
4.8 Hz, 1H, NH); 6.57 (d, J = 8.4 Hz, 2H, ArH3′′′′ and ArH5′′′′); 
6.34 (d, J = 7.5 Hz, 1H, NH); 6.19 (bs, 2H, NH); 6.08 – 5.94 (m, 1H, H2′′′′′); 5.79 – 5.60 (m, 1H, 
H2′); 5.37 (dd, J = 1.8, 17.1 Hz, 1H, H3a′′′′′); 5.26 (dd, J = 1.8, 10.5 Hz, 1H, H3b′′′′′); 5.11 (d, J = 
12.0 Hz, 1H, H3a′); 5.03 (d, J = 10.0 Hz, 1H, H3b′); 4.57 – 4.42 (m, 5H, H2, H5, H8 and H1′′′′′); 
3.70 (s, 3H, OCH3); 3.20 – 3.10 (m, 2H, H3′′); 3.01 – 2.98 (m, 2H, ArCH2); 2.63 (t, J = 6.3 Hz, 2H, 
H4′′′); 2.59 (s, 3H, 7′′′-CH3); 2.57 (s, 3H, 5′′′-CH3); 2.65 – 2.53 (m, 2H, H1′); 2.11 (s, 3H, 8′′′-CH3); 
1.96 (s, 3H, H11); 1.80 (t, J = 6.3 Hz, 2H, H3′′′); 1.60 – 1.48 (m, 2H, H6); 1.30 (s, 6H, 2 x 2′′′-
CH3).
 13
C NMR (CDCl3, 75 MHz): δ 171.6, C4; 171.5, C1; 171.3, C11; 169.4, C7; 156.7, ArC6′′′; 
156.0, ArC8a′′′; 152.4, CN3; 134.6, ArC7′′′; 134.1, ArC5′′′; 133.8, C2′′′′′; 133.7, C2′; 133.6, ArC4′′′; 
130.2, ArCH2′′′′ and ArCH6′′′′; 129.7, ArC8′′′; 122.7, ArC1′′′′; 118.0, ArC4a′′′; 117.7, C3′′′′′; 117.2, 
C3′; 114.1, ArCH3′′′′ and ArCH5′′′′; 73.4, C2′′′; 68.0, C1′′′′′; 54.5, C2; 52.0, C5; 51.7, OCH3; 51.6, 
C8; 40.1, C3′′; 39.8, ArCH2; 37.0, C4′′′; 32.1, C1′; 29.2, C7; 26.4, 2′′′-CH3; 25.1, C6; 22.4, C11; 
20.8, C3′′′; 18.2, 5′′′-CH3; 17.1, 7′′′-CH3; 11.9, 8′′′-CH3. MS (ESI, +ve) m/z 797 (40%) [MH
+
], 106 





























5.8. Synthesis of Protected Cyclic Tripeptides (10, 38 – 43) 
5.8.1. (7S,10R,13S,4E/Z)-13-Acetamido-8,11-diaza-10-(4-[tert-butoxycarboxamido]butyl)-7-
methoxycarbonyl-2-oxa-9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene (10) 
The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D), from 9 (277 mg, 0.46 mmol) to 
yield 10 (199 mg, 0.35 mmol, 75%) as a brown solid. Mp 178-180 
°C. 
1
H NMR (CDCl3, 300 MHz): δ 8.13 – 7.72 (m, 2H, NH); 7.13 – 
7.03 (m, 2H, ArH); 6.90 – 6.65 (m, 2H, ArH); 5.87 – 5.39 (m, 2H, 
H4 and H5); 4.65 – 4.36 (m, 4H, H7, H13 and H3); 4.20 – 4.06 (m, 
2H, NH and H10); 3.61 – 3.57 (m, 3H, OCH3); 2.87 – 2.69 (bs, 4H, 
H4′ and H14); 2.58 – 2.38 (m, 2H, H6); 1.82 – 1.75 (m, 3H, NCOCH3); 1.31 – 0.79 (m, 6H, H1′, 
H2′ and H3′); 1.35 (s, 9H, C(CH3)3).
 13
C NMR (CDCl3, 75 MHz): δ 172.8, C9; 172.3, 7-CO; 171.7, 
13-NCO; 171.6, C12; 157.2, NCO2; 156.5, 1-ArC1; 130.3, 1-ArCH2 and 1-ArCH6; 130.2, C4; 
128.6, C5; 127.6, 1-ArCH4; 117.7, 1-ArCH3 and 1-ArCH5; 78.7, C(CH3)3; 66.9, C3; 55.7, C13; 
54.4, C10; 54.1, C4′; 51.8, C4′; 40.1, C7; 36.0, C14; 29.4, C1′; 27.8, C6; 26.8, C3′; 26.2, C(CH3)3; 
22.6, NCOCH3; 21.7, C2′. MS (ESI, +ve) m/z 575.3 (20%) [MH
+
], 475.3 (100%) [MH
+
 - Boc)]. 




The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D) using 32 (311 mg, 0.52 mmol) to 
yield 38 as a mixture of epimers and E/Z iosomers (228 mg, 0.40 
mmol, 76%) as a brown solid. Mp 196-201 °C. 
1
H NMR (CDCl3, 
300 MHz): δ 7.62 – 7.46 (m, 2H, NH); 7.34 (bs, 1H, NH); 7.11 – 




































16.4 Hz, 1H, H4-trans); 5.57 – 5.36 (m, 1H, H5); 5.52 – 4.84 (m, 2H, H7 and H13); 4.76 – 4.56 (m, 
3H, H2 and H10); 3.80/3.77 (s, 3H, OCH3); 3.15 – 2.98 (m, 4H, H6 and H4′); 2.80 – 2.58 (m, 2H, 
H14); 2.10 (s, 3H, NCOCH3); 1.50 – 1.19 (m, 6H, H1′, H2′ and H3′); 1.44/1.40 (s, 9H, C(CH3)3).
 
13
C NMR (CDCl3, 75 MHz): δ 172.5, C9; 171.5/171.3, 7-CO; 170.8/170.7, 13-NCO; 170.0, C12; 
156.9, NCO2; 156.3, 1-ArC1; 130.1, 1-ArCH2 and 1-ArCH6; 128.5, C4; 128.1, C5; 127.7, 1-
ArCH4; 117.0/115.4, 1-ArCH3 and 1-ArCH5; 79.1, C(CH3)3; 66.2, C3; 55.0, C13; 53.2/53.0, C10; 
52.4, C4′; 40.5/39.7, C7; 35.9/35.1, C14; 29.8/29.4, C1′; 28.6, C6; 27.2/27.0, C3′; 26.6, C(CH3)3; 
23.7/23.4, NCOCH3; 22.7, C2′. MS (ESI, +ve) m/z 575.3 (25%) [MH
+
], 475.3 (40%) [MH
+
 - Boc)]. 





The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D), from 33 (104 mg, 0.13 mmol) to 
yield 39 (103 mg, 0.13 mmol, 100%) as a grey solid. Mp 172-175 °C. 
1
H NMR (CDCl3, 300 MHz): δ 7.18 – 6.98 (m, 2H, ArH); 6.88 – 6.62 
(m, 2H, ArH); 6.37 (bs, 1H, NH); 5.88 – 5.35 (m, H4 and H5); 4.95 – 
4.62 (m, 2H, H3); 4.62 – 4.22 (m, 3H, H7, H10 and H13); 3.63 (s, 3H, 
OCH3); 3.22 – 2.80 (m, 4H, H3′ and H6); 2.70 – 2.22 (m, 10H, H14, 7′′-CH3, 5′′-CH3 and H4′′); 
2.06 (s, 3H, 8′′-CH3); 1.90 (s, 3H, NCOCH3); 1.95 – 1.76 (m, 2H, H1′); 1.70 – 1.30 (m, 2H, H3′′); 
1.27 (s, 6H, 2 x 2′′-CH3).
 13
C NMR (CDCl3, 75 MHz): δ 172.0, COOCH3; 171.2, C11; 170.5, C9; 
170.3, NCOCH3; 157.1, ArC6′′; 156.2, CN3; 155.4, 1-ArC4; 153.3, ArC8a′′; 135.2, ArC5′′; 134.6, 
ArC7′′; 133.3, 1-ArCH2 and 1-ArCH6; 130.2, 1-ArC1; 128.4, C4; 128.3, C5; 123.9, ArC8′′; 117.8, 
ArC4a′′; 114.7, 1-ArCH3 and 1-ArCH5; 73.6, C2′′; 67.7, C3; 65.9, C7; 56.2, C10; 52.5, C13; 52.2, 


























5′′-CH3; 17.2, 7′′-CH3; 15.2, C2′; 12.2, 8′′-CH3. MS (ESI, -ve) m/z 767 (100%) [MH
+
]. HRMS calcd 





The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D), from 34 (127 mg, 0.16 mmol) to 
yield 40 (117 mg, 0.15 mmol, 95%) as a grey solid. Mp 224-228 °C. 
1
H NMR (CDCl3, 300 MHz): δ 7.18 – 6.82 (m, 2H, ArH); 6.77 – 
6.60 (m, 2H, ArH); 6.41 (bs, 1H, NH); 5.77 – 5.53 (m, H4 and H5); 
4.68 – 4.46 (bs, 5H, H3, H7, H10 and H13); 3.67 (s, 3H, OCH3); 
3.30 – 3.05 (m, 2H, H3′); 2.70 – 2.40 (m, 10H, H14, 7′′-CH3, 5′′-CH3 and H4′′); 2.08 (s, 3H, 8′′-
CH3); 1.78 (s, 3H, NCOCH3); 1.65 – 1.30 (m, 2H, H1′); 1.40 – 1.21 (m, 2H, H3′′); 1.30 (s, 6H, 2 x 
2′′-CH3).
 13
C NMR (CDCl3, 75 MHz): δ 172.0, COOCH3; 171.2, C11; 170.6, C9; 170.2, NCOCH3; 
156.3, ArC6′′; 156.2, CN3; 155.4, 1-ArC4; 153.3, ArC8a′′; 135.3, ArC5′′; 134.7, ArC7′′; 130.4, 1-
ArCH2 and 1-ArCH6; 129.7, 1-ArC1; 128.4, C4; 127.7, C5; 123.9, ArC8′′; 117.8, ArC4a′′; 115.2, 
1-ArCH3 and 1-ArCH5; 73.6, C2′′; 67.7, C3; 65.9, C7; 56.2, C10; 52.6, C13; 52.2, C3′; 51.7, 
OCH3; 40.1, C6; 34.9, C14; 33.6, NCOCH3; 26.8, 2′′-CH3; 21.5, C3′′; 18.7, C4′′; 17.6, 5′′-CH3; 
17.2, 7′′-CH3; 15.2, C2′; 12.2, 8′′-CH3. MS (ESI, +ve) m/z 769 (100%) [MH
+
]. HRMS calcd for 






























The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D), from 35 (170 mg, 0.210 mmol) to 
yield 41 (160 mg, 0.210 mmol, 99%) as a grey solid. Mp 205-207 °C. 
1
H NMR (CD3OD, 300 MHz): δ 8.10 – 8.00 (m, 2H, NH); 7.10 – 
6.95 (m, 2H, ArH); 6.80 – 6.60 (m, 2H, ArH); 6.48 (bs, 1H, NH); 
5.90 – 5.60 (m, 2H, NH); 5.60 – 5.30 (m, H4 and H5); 4.62 (bs, 2H, 
H3); 4.60 – 4.25 (m, 3H, H7, H10 and H13); 3.66 (s, 3H, OCH3); 3.30 – 2.80 (m, 4H, H3′ and 
H14); 2.70 – 2.50 (m, 6H, 5′′-CH3 and 7′′-CH3); 2.50 – 2.30 (m, 2H, H4′′); 2.00 (s, 3H, 8′′-CH3); 
1.75 (s, 3H, NCOCH3); 1.60 – 1.40 (m, 2H, H1′); 1.34 (bs, 2H, H3′′); 1.27 (s, 6H, 2 x 2′′-CH3).
 13
C 
NMR (CD3OD, 125 MHz): δ 171.8, COOCH3; 171.7, C11; 171.4, C9; 171.1, NCOCH3; 157.0, 
ArC6′′; 155.9, CN3; 155.5, 1-ArC4; 152.4, ArC8a′′; 134.2, ArC5′′; 134.0, ArC7′′; 130.4, 1-ArCH2 
and 1-ArCH6; 129.6, 1-ArC1; 128.7, C4; 127.5, C5; 122.8, ArC8′′; 117.7, ArC4a; 114.2, 1-ArCH3 
and 1-ArCH5; 73.5, C2′′; 66.4, C3; 55.0, C7; 53.3, C10; 52.9, C13; 52.3, C3′; 51.9, OCH3; 40.6, 
C6; 37.4, C14; 32.2, NCOCH3; 26.7, 2′′-CH3; 22.5, C3′′; 21.0, C4′′; 18.2, 5′′-CH3; 17.2, 7′′-CH3; 
15.2, C2′; 12.0, 8′′-CH3. MS (ESI, -ve) m/z 769.5 (85%) [MH
+
]. HRMS calcd for C38H53N6O9S 






























The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D), from 36 (262 mg, 0.330 mmol) to 
yield 42 (217 mg, 0.280 mmol, 86%) as a grey solid. Mp 174-176 
°C. 
1
H NMR (d6DMSO, 500 MHz): δ 8.28 – 8.09 (m, 2H, NH); 7.11 
– 7.01 (m, 2H, ArH); 6.77 – 6.72 (m, 2H, ArH); 6.54 - 6.44 (bs, 1H, 
NH); 5.72 – 5.68 (m, 2H, NH); 5.41 – 5.34 (m, H4 and H5); 4.62 
(bs, 2H, H3); 4.52 – 4.04 (m, 3H, H7, H10 and H13); 3.55 (s, 3H, OCH3); 3.06 – 2.96 (m, 2H, H3′); 
2.92 – 2.67 (m, 2H, H14); 2.60 – 2.50 (m, 6H, 5′′-CH3 and 7′′′-CH3); 2.35 – 2.20 (m, 2H, H4′′); 2.00 
(s, 3H, 8′′-CH3); 1.73 (s, 3H, NCOCH3); 1.67 – 1.44 (m, 2H, H1′); 1.35 (bs, 2H, H3′′); 1.23 (s, 6H, 
2 x 2′′-CH3).
 13
C NMR (d6DMSO, 125 MHz): δ 171.7, COOCH3; 171.5, C11; 171.3, C9; 171.1, 
NCOCH3; 156.6, ArC6′′; 155.8, CN3; 155.4, 1-ArC4; 152.2, ArC8a′′; 134.4, ArC5′′; 133.9, ArC7′′; 
130.0, 1-ArCH2 and 1-ArCH6; 129.5, 1-ArC1; 128.8, C4; 127.5, C5; 122.6, ArC8′′; 117.6, ArC4a′′; 
114.1, 1-ArCH3 and 1-ArCH5; 73.4, C2′′; 66.4, C3; 54.9, C7; 53.3, C10; 52.6, C13; 52.2, C3′; 51.9, 
OCH3; 40.6, C6; 37.2, C14; 32.2, NCOCH3; 26.5, 2′′-CH3; 22.5, C3′′; 20.8, C4′′; 18.2, 5′′-CH3; 
17.2, 7′′-CH3; 15.2, C2′; 12.0, 8′′-CH3. MS (ESI, +ve) m/z 767 (65%) [MH
+
]. HRMS calcd for 





























The title compound was prepared using the general procedure for 
olefin metathesis (Procedure D), from 37 (366 mg, 0.46 mmol) to 
yield 43 (307 mg, 0.40 mmol, 87%) as a grey solid. Mp 186-190 °C. 
1
H NMR (d6DMSO, 500 MHz): δ 8.20 – 7.85 (m, 3H, NH); 7.15 – 
6.98 (m, 2H, ArH); 6.85 – 6.60 (m, 2H, ArH); 6.41 (bs, 1H, NH); 6.00 
– 5.60 (m, 1H H5); 5.60 – 5.38 (m, 1H, H4); 4.65 – 4.10 (m, 5H, H3, 
H7, H10 and H13); 3.69 (s, 3H, OCH3); 3.30 – 3.10 (m, 2H, H3′); 2.90 – 2.62 (m, 2H, H4′′); 2.60 – 
2.50 (m, 8H, H14, 7′′-CH3, and 5′′-CH3); 2.08 (s, 3H, 8′′-CH3); 1.85 (s, 3H, NCOCH3); 1.70 – 1.60 
(m, 2H, H1′); 1.50 – 1.30 (m, 2H, H3′′); 1.26 (s, 6H, 2 x 2′′-CH3).
 13
C NMR (d6DMSO, 125 MHz): δ 
171.8, COOCH3; 171.6, C11; 170.8, C9; 169.5, NCOCH3; 156.8, ArC6′′; 156.4, CN3; 156.0, 1-
ArC4; 152.4, ArC8a′′; 134.6, ArC5′′; 134.5, ArC7′′; 130.2, 1-ArCH2 and 1-ArCH6; 129.4, 1-ArC1; 
128.3, C4; 127.9, C5; 122.7, ArC8′′; 117.8, ArC4a; 114.9, 1-ArCH3 and 1-ArCH5; 73.5, C2′′; 67.0, 
C3; 66.9, C7; 54.8, C10; 54.5, C13; 51.9, C3′; 51.8, OCH3; 40.1, C6; 36.8, C14; 32.1, NCOCH3; 
26.5, 2′′-CH3; 22.4, C3′′; 20.8, C4′′; 18.2, 5′′-CH3; 17.2, 7′′-CH3; 15.2, C2′; 12.0, 8′′-CH3. MS (ESI, 
+ve) m/z 769 (40%) [MH
+
], 106 (100%). HRMS calcd for C38H53N6O9S 769.3595, found 769.3600. 
 
5.9. Synthesis of Tripeptide hydrochloride salts (11, 44 – 49) 
5.9.1. (7S,10R,13S,4E/Z)-13-Acetamido-10-(4-aminobutyl)-8,11-diaza-7-methoxycarbonyl-2-oxa-
9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene hydrochloride (11) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 10 (49 mg, 0.084 mmol) 
to yield 11 (17 mg, 0.033 mmol, 49%) as a highly hygroscopic yellow 
solid.
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NH); 6.85 (bs, 1H, NH); 6.71 (d, J = 7.5 Hz, 2H, ArH); 6.03 – 5.68 (m, 2H, H4 and H5); 4.50 – 
4.02 (m, 5H, H3, H7, H10 and H13); 3.68 (s, 3H, OCH3); 2.93 – 2.48 (m, 4H, H6 and H4′); 1.93 (s, 
3H, NCOCH3); 1.80 – 0.83 (m, 6H, H1′, H2′ and H3′).
 13
C NMR (CD3OD, 75 MHz):  δ 173.5, C9; 
173.1, 7-CO; 173.0, 13-NCO; 172.6, C12; 157.7, 1-ArC1; 132.4, 1-ArCH2 and 1-ArCH6; 131.1, 
C4; 129.6, C5; 129.3, 1-ArC4; 116.8, 1-ArCH3 and 1-ArCH5; 70.0, C3; 57.9, C13; 54.9, C10; 53.5, 
C4′; 53.0, OCH3; 40.7, C7; 38.2, C14; 32.1, C1′; 31.7, C6; 28.0, C3′; 23.5, NCOCH3; 22.6, C2′. MS 
(ESI, +ve) m/z 475.3 (100%) [MH
+
]. HRMS calcd for C24H35N4O6 475.2557, found 475.2534. 
 
5.9.2. (7S,10S,13S,4E/Z)-13-Acetamido-10-(4-aminobutyl)-8,11-diaza-7-methoxycarbonyl-2-oxa-
9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene hydrochloride (44) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A) using 38 (220 mg, 0.380 
mmol) to yield 44 as a mixture of epimers and E/Z iosomers (152 
mg, 0.300 mmol, 79%) as a highly hygroscopic yellow solid.
 1
H 
NMR (CD3OD, 300 MHz): δ 8.19 (d, J = 8.4 Hz, 1H, NH); 6.98/6.92 
(d, J = 8.0 Hz, 2H, ArH); 6.74/6.64 (d, J = 8.0 Hz, 2H, ArH); 5.57 (d, J = 16.0 Hz, 2H, H4-trans); 
5.46 – 5.35 (m, 1H, H5); 4.56 – 4.37 (m, 4H, H7, H13 and H2); 4.26 – 4.19 (m, 1H, H10); 3.93 (bs, 
1H, NH); 3.63/3.60 (s, 3H, OCH3); 2.89 – 2.57 (m, 6H, H6, H4′ and H14); 1.99/1.89 (s, 3H, 
NCOCH3); 1.73 – 1.58 (m, 2H, H2′); 1.58 – 1.42 (bs, 2H, H3′); 1.35 – 1.16 (m, 2H, H1′). 
13
C NMR 
(CD3OD, 75 MHz): δ 174.5, C9; 173.3, 7-CO; 173.1, 13-NCO; 172.5, C12; 157.7, 1-ArC1; 131.4, 
1-ArCH2 and 1-ArCH6; 131.1, C4; 129.5, C5; 129.1, 1-ArC4; 116.4, 1-ArCH3 and 1-ArCH5; 66.9, 
C3; 57.7, C13; 53.9, C10; 53.1, C4′; 53.0, OCH3; 40.5, C7; 38.1, C14; 32.0, C1′; 31.8, C6; 28.0, 
C3′; 23.5, NCOCH3; 22.5, C2′. MS (ESI, +ve) m/z 475.4 (100%) [MH
+
]. HRMS calcd for 




















The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 39 (60 mg, 0.078 mmol) 
to yield 45 (38 mg, 0.071 mmol, 91%) as a white solid. Mp 218-224 
°C. 
1
H NMR (CD3OD, 300 MHz): δ 7.14 – 7.05 (m, 2H, ArH); 6.85 – 
6.68 (m, 2H, ArH); 5.86 – 5.70 (m, 1H, H5); 5.11 – 4.95 (m, 1H, 
H4); 4.68 – 4.44 (m, 5H, H3, H7, H10 and H13); 3.73 – 3.69 (m, 3H, OCH3); 3.30 – 3.10 (m, 2H, 
H3′); 3.04 – 2.94 (m, 2H, H14); 2.81 – 2.48 (m, 2H, H6); 1.94 (s, 3H, NCOCH3); 1.71 – 1.91 (m, 
2H, H1′); 1.41 - 1.33 (m, 2H, H2′).
 13
C NMR (CD3OD, 75 MHz): δ 173.6, COOCH3; 173.5, C11; 
173.1, C9; 172.4, NCOCH3; 158.4, CN3; 157.4, 1-ArC4; 131.5, C4; 129.5, C5; 129.1, 1-ArCH2 and 
1-ArCH6; 129.0, 1-ArC1; 116.5, 1-ArCH3 and 1-ArCH5; 66.9, C3; 57.5, C7; 56.2, C10; 54.3, C10; 
53.6, C3′; 52.5, OCH3; 42.1, C6; 38.7, C14; 35.3, NCOCH3; 26.6, C1′; 22.7, C2′. MS (ESI, +ve) 
m/z 503 (100%) [MH
+
]. HRMS calcd for C24H35N6O6 503.2618, found 503.2626. 
 
5.9.4. (7S,10S,13S,4E/Z)-13-Acetamido-8,11-diaza-10-(3-[guanidino]propyl)-7-methoxycarbonyl-
2-oxa-9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene hydrochloride (46) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 40 (91 mg, 0.12 mmol) to 
yield 46 as a white solid (38 mg, 0.076 mmol, 59%). Mp 218-220 °C. 
1
H NMR (CD3OD, 300 MHz): δ 7.14 – 7.04 (m, 2H, ArH); 6.85 – 6.68 
(m, 2H, ArH); 5.80 – 5.65 (m, 1H, H5); 5.55 – 5.35 (m, 1H, H4); 4.65 
– 4.10 (m, 5H, H3, H7, H10 and H13); 3.68 (bs, 3H, OCH3); 3.18 – 3.00 (m, 2H, H3′); 3.00 – 2.85 
(m, 2H, H14); 2.70 – 2.40 (m, 2H, H6); 1.99 (s, 3H, NCOCH3); 1.80 – 1.65 (m, 2H, H1′); 1.65 – 
1.40 (m, 2H, H2′).
 13
C NMR (CD3OD, 75 MHz): δ 173.5, COOCH3; 173.3, C11; 173.2, C9; 172.2, 








































1-ArC1; 116.2, 1-ArCH3 and 1-ArCH5; 66.8, C3; 57.6, C7; 56.0, C10; 54.1, C10; 53.6, C3′; 52.9, 
OCH3; 42.0, C6; 38.0, C14; 35.3, NCOCH3; 26.2, C1′; 22.6, C2′. MS (ESI, +ve) m/z 503 (100%) 
[MH
+
]. HRMS calcd for C24H35N6O6 503.2618, found 503.2603. 
 
5.9.5. (7R,10R,13S,4E/Z)-13-Acetamido-8,11-diaza-10-(3-[guanidino]propyl)-7-methoxycarbonyl-
2-oxa-9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene hydrochloride (47) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 41 (108 mg, 0.140 
mmol) to yield 47 (25 mg, 0.049 mmol, 35%) as a white solid. Mp 
170-176 °C. 
1
H NMR (CD3OD, 300 MHz): δ 7.14 – 7.04 (m, 2H, 
ArH); 6.83 – 6.70 (m, 2H, ArH); 6.08 – 5.79 (m, 1H, H5); 5.54 – 
5.45 (m, 1H, H4); 4.66 – 4.12 (m, 5H, H3, H7, H10 and H13); 3.70 – 3.68 (m, 3H, OCH3); 3.13 – 
3.02 (m, 2H, H3′); 3.00 – 2.85 (m, 2H, H14); 2.57 – 2.37 (m, 2H, H6); 1.94 (s, 3H, NCOCH3); 1.80 
– 1.45 (m, 2H, H1′); 1.42 – 1.28 (m, 2H, H2′).
 13
C NMR (CD3OD, 75 MHz): δ 173.8, COOCH3; 
173.5, C11; 173.2, C9; 172.6, NCOCH3; 158.4, CN3; 157.2, 1-ArC4; 131.4, C4; 130.6, C5; 129.7, 
1-ArCH2 and 1-ArCH6; 129.3, 1-ArC1; 115.9, 1-ArCH3 and 1-ArCH5; 67.3, C3; 57.2, C7; 54.0, 
C10; 53.7, C13; 53.2, C3′; 52.9, OCH3; 42.0, C6; 37.9, C14; 35.2, NCOCH3; 26.1, C1′; 22.6, C2′. 
MS (ESI, +ve) m/z 503 (35%) [MH
+
]. HRMS calcd for C24H35N6O6 503.2618, found 503.2644. 
 
5.9.6. (7R,10S,13S,4E/Z)-13-Acetamido-8,11-diaza-10-(3-[guanidino]propyl)-7-methoxycarbonyl-
2-oxa-9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene hydrochloride (48) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 42 (129 mg, 0.16 mmol) 
to yield 48 as a white solid (71 mg, 0.14 mmol, 86%). Mp 134-138 
°C. 
1
H NMR (CD3OD, 300 MHz): δ 7.18 – 7.04 (m, 2H, ArH); 6.88 – 








































4.65 – 4.26 (m, 5H, H3, H7, H10 and H13); 3.72/3.69 (2 x s, 3H, OCH3, 2 rotomers 1:3); 3.31 – 
3.29 (m, 2H, H3′); 2.25 – 2.82 (m, 2H, H14); 2.70 – 2.40 (m, 2H, H6); 1.94 (s, 3H, NCOCH3); 1.90 
– 1.74 (m, 2H, H1′); 1.69 – 1.53 (m, 2H, H2′).
 13
C NMR (CD3OD, 75 MHz): δ 174.0, COOCH3; 
173.6, C11; 173.3, C9; 173.0, NCOCH3; 158.4, CN3; 157.2, 1-ArC4; 131.3, C4; 130.6, C5; 129.7, 
1-ArCH2 and 1-ArCH6; 129.5, 1-ArC1; 115.8, 1-ArCH3 and 1-ArCH5; 67.7, C3; 57.8, C7; 54.9, 
C10; 54.0, C10; 53.2, C3′; 52.9, OCH3; 42.0, C6; 37.7, C14; 33.2, NCOCH3; 26.5, C1′; 22.3, C2′. 
MS (ESI, +ve) m/z 503.4 (100%) [MH
+




The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 43 (128 mg, 0.17 mmol) 
to yield 49 as a highly hygroscopic solid (29 mg, 0.058 mmol, 34%). 
1
H NMR (CD3OD, 300 MHz): δ 8.39 – 8.06 (m, 3H, NH); 7.63 (bs, 
1H, NH); 7.16 – 7.00 (m, 2H, ArH); 6.83 – 6.64 (m, 2H, ArH); 5.88 – 
5.78 (m, 1H, H5); 5.39 – 5.08 (m, 1H, H4); 4.67 – 4.19 (m, 5H, H3, H7, H10 and H13); 3.58 (bs, 
3H, OCH3); 3.15 – 2.98 (m, 2H, H3′); 2.92 – 2.60 (m, 2H, H14); 2.59 – 2.30 (m, 2H, H6); 1.77 (s, 
3H, NCOCH3); 1.84 – 1.66 (m, 2H, H1′); 1.39 – 1.26 (m, 2H, H2′).
 13
C NMR (CD3OD, 75 MHz): δ 
171.3, COOCH3; 171.6, C11; 171.3, C9; 169.4, NCOCH3; 156.8, CN3; 155.8, 1-ArC4; 130.2, C4; 
128.8, C5; 128.2, 1-ArCH2 and 1-ArCH6; 127.9, 1-ArC1; 114.9, 1-ArCH3 and 1-ArCH5; 67.1, C3; 
55.2, C7; 54.7, C10; 52.9, C10; 51.8, C3′; 51.6, OCH3; 42.0, C6; 36.9, C14; 33.9, NCOCH3; 29.0, 
C1′; 22.4, C2′. MS (ESI, +ve) m/z 503 (30%) [MH
+
], 102 (100%). HRMS calcd for C24H35N6O6 






















5.10 Synthesis of Dipeptide Hydrocholride Salts (Scheme 5, 50 – 53) 
5.10.1. Methyl (2S,5R)-2-allyl-3-aza-5-(9H-9-fluorenylmethyloxycarboxamido)-8-(guanidino)-4-
oxooctanoate hydrochloride (50) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 23 (81 mg, 0.105 
mmol) giving 50 (43 mg, 0.079 mmol, 75%). as a highly 
hygroscopic solid; [α]D
23
 +17.7 (c 0.008, MeOH). IR (neat) νmax 
1662, 1540, 1210, 1178, 1098, 1030, 1004, 742. Mp 203-208 °C. 
1
H NMR (CD3OD, 300 MHz): δ 7.88 – 7.85 (m, 2H, ArH1′′ and ArH8′′); 7.66 – 7.77 (m, 2H, 
ArH4′′ and ArH5′′); 7.45 – 7.27 (m, 4H, ArH3′′ and ArH6′′ and ArH2′′ and ArH7′′); 5.81 – 5.71 (m, 
1H, H2′); 5.16 – 5.03 (m, 2H, H3); 4.46 (dd, J = 5.4, 8.4 Hz, 1H, H2); 4.39 (d, J = 6.3 Hz, 2H, 
OCH2-H9′′); 4.35 – 4.29 (m, 1H, H5); 4.2 – 4.15 (m, 1H, H9′′); 3.68 (s, 3H, OCH3); 3.17 (bs, 2H, 
H8); 2.61 – 2.41 (m, Hz, 2H, H1′); 1.88 – 1.75 (m, 2H, H7); 1.75 – 1.55 (m, 2H, H6).
 13
C NMR 
(CD3OD, 75 MHz): δ 174.1, C4; 172.9, C1; 158.4, 5-NCO2; 146.3, ArC8a′′ and ArC9a′′; 142.4, 
ArC4a and ArC4b; 134.1, C2′; 129.1, ArCH3′′ and ArCH6′′; 128.0, ArCH2′′ and ArCH7′′; 126.6, 
ArCH4′′ and ArCH5′′; 120.8, ArCH1′′ and ArCH8′′; 118.9, C3′; 67.9, CH2-C9′′; 55.8, C9′′; 53.4, 
C2; 52.8, OCH3; 51.1, C5; 42.0, C8; 36.8, C1′; 30.5, H7; 26.3, H6. MS (ESI, +ve) m/z 508 (100%) 
[MH
+
]. HRMS calcd for C27H34N5O5 508.2526, found 508.2570. 
 
5.10.2. Methyl (2S,5S)-2-allyl-3-aza-5-(9H-9-fluorenylmethyloxycarboxamido)-8-(guanidino)-4-
oxooctanoate hydrochloride (51) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A) using 24 (81 mg, 0.105 
mmol) giving 51 (27 mg, 0.05 mmol, 47%) as a highly 
hygroscopic solid; [α]D
23
 +6.4 (c 0.005, MeOH). IR (neat) νmax 






































NMR (CD3OD, 500 MHz): δ 7.79 (d, J = 7.5 Hz, 2H, ArH1′′ and ArH8′′); 7.68 – 7.56 (m, 2H, 
ArH4′′ and ArH5′′); 7.44 – 7.27 (m, 4H, ArH3′′ and ArH6′′ and ArH2′′ and ArH7′′); 5.81 – 5.65 (m, 
1H, H2′); 5.15 – 5.02 (m, 2H, H3′); 4.46 (dd, J = 6.0, 8.1 Hz, 1H, H2); 4.34 (d, J = 7.2 Hz, 2H, 
OCH2-H9′′); 4.34 – 4.28 (m, 1H, H5); 4.22 – 4.12 (m, 1H, H9′′); 3.71/3.69 (2 x s, 3H, OCH3, 2 
rotomers 1:3); 3.28 – 3.08 (m, 2H, H8); 2.59 – 2.40 (m, 2H, H1′); 1.95 – 1.72 (m, 2H, H7); 1.75 – 
1.52 (m, 2H, H6).
 13
C NMR (CD3OD, 75 MHz): δ 174.4, C4; 173.2, C1; 158.4, CN3; 158.3, 5-
NCO2; 144.2, ArC8a′′ and ArC9a′′; 142.4, ArC4a′′ and ArC4b′′; 134.1, C2′; 129.1, ArCH3′′ and 
ArCH6′′; 128.7, ArCH2′′ and ArCH7′′; 126.7, ArCH4′′ and ArCH5′′; 120.9, ArCH1′′ and ArCH8′′; 
119.0, C3′; 67.9, CH2-C9′′; 55.6, C9′′; 53.5, C2; 52.8, OCH3; 48.1, C5; 42.0, C8; 36.6, C1′; 30.3, 
H7; 26.2, H6. MS (ESI, +ve) m/z 508 (100%) [MH
+




oxooctanoate hydrochloride (52) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 25 (80 mg, 0.10 
mmol) to yield 52 (45 mg, 0.083 mmol, 80%) as a highly 
hygroscopic white solid; [α]D
23
 -50.6 (c 0.002, MeOH). IR 
(neat) νmax 1715, 1653, 1558, 1540, 1212, 1046, 738. 
1
H NMR 
(CD3OD, 500 MHz): δ 7.61 (d, J = 7.5 Hz, 2H, ArH1′′ and ArH8′′); 7.47 (d, J = 8.5 Hz, 2H, ArH4′′ 
and ArH5′′); 7.20 (t, J = 7.5 Hz, 2H, ArH3′′ and ArH6′′); 7.12 (t, J = 7.5 Hz, 2H, ArH2′′ and 
ArH7′′); 5.62 – 5.54 (m, 1H, H2′); 4.93 (d, J = 17.0 Hz, 1H, H3a′); 4.87 (d, J = 10.0 Hz, 1H, H3b′); 
4.28 (dd, J = 6.0, 8.0 Hz, 1H, H2); 4.20 (d, J = 7.0 Hz, 2H, OCH2-H9′′); 4.03 (t, J = 7.0 Hz, 1H, 
H5); 3.99 (t, J = 7.0 Hz, 1H, H9′′); 3.51 (s, 3H, OCH3); 3.01 (bs, 2H, H8); 2.41 – 2.26 (m, 2H, H1′); 
1.64 (bs, 2H, H7); 1.47 (bs, 2H, H6).
 13
C NMR (CD3OD, 75 MHz): δ 174.1, C4; 173.1, C1; 158.4, 



















ArCH3′′ and ArCH6′′; 128.0, ArCH2′′ and ArCH7′′; 126.0, ArCH4′′ and ArCH5′′; 120.8, ArCH1′′ 
and ArCH8′′; 118.8, C3′; 67.9, CH2-C9′′; 55.6, C9′′; 53.6, C2; 52.7, OCH3; 49.3, C5; 42.1, C8; 36.7, 
C1′; 30.4, C7; 26.2, C6. MS (ESI, +ve) m/z 508 (45%) [MH
+
]. HRMS calcd for C27H34N5O5 
508.2560, found 508.2592. 
 
5.10.4. Methyl (2R,5S)-2-allyl-3-aza-5-(9H-9-fluorenylmethyloxycarboxamido)-8-(guanidino)-4-
oxooctanoate hydrochloride (53) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A) using 26 (94 mg, 0.12 
mmol) to yield 53 (33 mg, 0.061 mmol, 51%) as a highly 
hygroscopic white solid; [α]D
22
 -19.6 (c 0.005, MeOH). IR (neat) 
νmax 1662, 1537, 1213, 1107, 1050, 1031, 738. 
1
H NMR (CD3OD, 
300 MHz): δ 7.79 (d, J = 7.5 Hz, 2H, ArH1′′ and ArH8′′); 7.67 – 7.63 (m, 2H, ArH4′′ and ArH5′′); 
7.39 (t, J = 7.2 Hz, 2H, ArH3′′ and ArH6′′); 7.30 (t, J = 7.2 Hz, 2H, ArH2′′ and ArH7′′); 5.78 – 5.65 
(m, 1H, H2′); 5.09 (d, J = 16.5 Hz, 1H, H3a′); 5.04 (d, J = 9.6 Hz, 1H, H3b′); 4.46 (dd, J = 5.7, 8.4 
Hz, 1H, H2); 4.40 (d, J = 6.3 Hz, 2H, OCH2-H9′′); 4.22 (t, J = 6.6 Hz, 1H, H5); 4.24 – 4.13 (m, 1H, 
H9′′); 3.69 (s, 3H, OCH3); 3.17 (t, J = 6.6 Hz, 2H, H8); 2.60 – 2.40 (m, 2H, H1′); 1.86 – 1.78 (m, 
2H, H7); 1.67 – 1.50 (m, 2H, H6).
 13
C NMR (CD3OD, 75 MHz): δ 174.0, C4; 172.9, C1; 158.4, 
CN3; 158.2, 5-NCO2; 145.1, ArC8a′′ and ArC9a′′; 142.4, ArC4a′′ and ArC4b′′; 134.1, C2′; 128.7, 
ArCH3′′ and ArCH6′′; 128.0, ArCH2′′ and ArCH7′′; 126.0, ArCH4′′ and ArCH5′′; 120.8, ArCH1′′ 
and ArcH8′′; 118.9, C3′; 67.9, CH2-C9′′; 55.8, C9′′; 53.4, C2; 52.8, OCH3; 49.3, C5; 42.0, C8; 36.8, 
C1′; 30.5, C7; 26.3, C6. MS (ESI, +ve) m/z 508 (25%) [MH
+
], 179 (100%) [Sodium 




















5.11. Synthesis of Acyclic Tripeptide hydrochloride salts (Scheme 6: 54 – 59) 
5.11.1. Methyl (2S,5R,8S)-2-allyl-8-(4-allyloxyphenyl)-5-(4-aminobutyl)-3,6,9-triaza-4,7,10-
trioxoundecanoate hydrochloride (54) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 9 (64 mg, 0.11 mmol) 
to yield 54 (22 mg, 0.041 mmol, 37%) as a cream coloured highly 
hygroscopic solid. 
1
H NMR (CD3OD, 500 MHz): δ 7.15 (d, J = 8.0 
Hz, 2H, ArH2′′′ and ArH6′′′); 6.87 (d, J = 8.0 Hz, 2H, ArH3′′′ and 
ArH5′′′); 6.09 – 6.01 (m, 1H, H2′′′′); 5.77 – 5.69 (m, 1H, H2′); 5.39 (d, J = 17.0 Hz, 1H, H3′′′′); 5.24 
(d, J = 10.5 Hz, 1H, H3′′′′); 5.08 (d, J = 17.0 Hz, 1H, H3′); 5.04 (d, J = 10.0 Hz, 1H, H3′); 4.52 (d, J 
= 5.5 Hz, 2H, H1′′′′); 4.43 – 4.37 (m, 2H, H2 and H5); 4.15 (d, J = 6.5 Hz, 1H, H8); 3.69 (s, 3H, 
OCH3); 2.96 – 2.90 (m, 2H, H1′); 2.83 (bs, 2H, H4′′); 2.60 – 2.48 (m, 2H, ArCH2); 1.93 (s, 3H, 
H11); 1.74 (bs, 2H, H1′′); 1.50 (bs, 2H, H2′′); 1.00 (bs, 2H, H3′′).
 13
C NMR (CD3OD, 75 MHz): δ 
174.3, C7; 173.7, C1; 173.2, C4; 173.1, C10; 158.8, ArC4′′′; 134.8, C2′; 134.5, C2′′′′; 131.3, 
ArCH2′′′ and ArCH6′′′; 129.9, ArC1′′′; 118.4, C3′; 117.5, C3′′′′; 115.8, ArCH3′′′ and ArCH5′′′; 
69.8, C1′′′′; 57.6, C5; 54.2, OCH3; 53.8, C8; 52.7, C2; 40.3, C4′; 37.4, ArCH2; 36.4, C1′; 31.7, C1′′; 
28.0, C3′′; 23.5, C11; 22.4, C2′′. MS (ESI, +ve) m/z 503.7 (100%) [MH
+
]. HRMS calcd for 
C26H39N4O6 503.2870, found 503.2881. 
 
5.11.2. Methyl (2S,5S,8S)-8-acetamido-2-allyl-9-(4-allyloxyphenyl)-5-(4-aminobutyl)-3,6-diaza-4,7-
dioxononanoate hydrochloride (55) 
The title compound was synthesized using the general procedure 
(Procedure A), by deprotection of 32 (104 mg, 0.170 mmol) to yield 
55 as a 1:1 mixture of epimers (55 mg, 0.10 mmol, 60%) as a 
highly hygroscopic yellow solid. Mp 150-154 °C. 
1
H NMR 








































ArH6′′′); 6.84 (t, J = 8.0 Hz, 2H, ArH3′′′ and ArH5′′′); 6.08 – 5.99 (m, 1H, H2′′′′); 5.81 – 5.73 (m, 
1H, H2′); 5.37 (d, J = 17.3 Hz, 1H, H3a′′′′); 5.22 (d, J = 9.7 Hz, 1H, H3b′′′′); 5.15 – 5.04 (m, 2H, 
H3′); 4.52 – 4.36 (m, 5H, H2, H5, H8 and H1′′′′); 3.69/3.67 (s, 3H, OCH3); 3.08 – 2.76 (m, 4H, H1′ 





NMR (CD3OD, 75 MHz): δ 173.7/173.6, C7; 173.4, C1; 173.1, C4; 173.0/172.9, C10; 158.7, 
ArCH4′′′; 134.8, C2′; 134.3/134.0, C2′′′′; 131.2/131.1, ArCH2′′′ and ArCH6′′′; 130.2/130.1, ArC1′′′; 
118.8/118.5, C3′; 117.4/117.3, C3′′′′; 115.7/115.6, ArCH3′′′ and ArCH5′′′; 69.8/69.7, C1′′′′; 57.2, 
C5; 54.0, OCH3; 53.8/53.7, C8; 52.8/52.7, C2; 40.6/40.5, C4′; 37.8/37.7, ArCH2; 36.6/36.5, C1′; 
31.9, C1′′; 28.0, C3′′; 23.4, C11; 22.5, C2′′. MS (ESI, +ve) m/z 503.3 (100%) [MH
+
]. HRMS calcd 
for C26H39N4O6 503.2870, found 503.2894. 
 
5.11.3. Methyl (2S,5R,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-(3-[guanidino]propyl)-4,7,10-
oxoundecanoate hydrochloride (56) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 33 (70 mg, 0.088 mmol) 
to yield 56 (37 mg, 0.065 mmol, 74%) as a highly hygroscopic solid; 
[α]D
24
 +17.4 (c 0.007, MeOH). IR (neat) νmax 1734, 1652, 1543, 1507, 
1445, 1217, 1052, 1000, 767. 
1
H NMR (CD3OD, 300 MHz): δ 7.12 
(d, J = 7.5 Hz, 2H, ArH2′′′ and ArH6′′′); 6.83 (d, J = 7.5 Hz, 2H, ArH3′′′ and ArC5′′′); 6.05 – 5.96 
(m, 1H, H2′′′′); 5.76 – 6.64 (m, 1H, H2′); 5.35 (d, J = 17.4 Hz, 1H, H3a′′′′); 5.19 (d, J = 9.9 Hz, 1H, 
H3b′′′′); 5.08 – 5.02 (m, 2H, H3′); 4.48 – 4.47 (m, 2H, H2′′′′); 4.42 – 4.342 (m, 2H, H2 and H5); 
4.18 – 4.14 (m, 1H, H8); 3.65 (s, 3H, OCH3); 3.36 – 3.26 (m, 2H, H3′′); 3.06 – 2.96 (m, 2H, 
ArCH2); 2.54 – 2.46 (m, 2H, H1′); 1.92 (s, 3H, H11); 1.85 – 1.64 (m, 2H, H1′′); 1.40 – 1.16 (m, 2H, 
H2′′). 
13
C NMR (CD3OD, 75 MHz): δ 174.0, C4; 173.4, C11; 172.9, C1; 169.0, C7; 158.8, ArC4′′′; 
158.2, CN3; 134.7, C2′′′′; 134.3, C2′; 131.2, ArC1′′′; 129.8, ArCH2′′′ and ArCH6′′′; 118.4, C3′; 
























50.1, C3′′; 37.5, ArCH2; 36.4, C1′; 29.5, C2′′; 24.0, C11; 22.3, C1′′. MS (ESI, +ve) m/z 531 (100%) 
[MH
+
]. HRMS calcd for C26H39N6O6 531.2931, found 531.2939. 
 
5.11.4. Methyl (2S,5S,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-(3-[guanidino]propyl)-4,7,10-
oxoundecanoate hydrochloride (57) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 34 (63 mg, 0.079 
mmol) to yield 57 (38 mg, 0.036 mmol, 85%) as a highly 
hygroscopic solid; [α]D
21
 +46.1 (c 0.001, MeOH). IR (neat) νmax 
1740, 1631, 1543, 1512, 1254, 1093. 
1
H NMR (CD3OD, 300 MHz): 
δ 7.13 (d, J = 8.7 Hz, 2H, ArH2′′′ and ArH6′′′); 6.82 (d, J = 8.7 Hz, 
2H, ArH3′′′ and ArH5′′′); 6.09 – 5.97 (m, 1H, H2′′′′); 5.84 – 5.70 (m, 1H, H2′); 5.36 (dd, J = 1.5, 
17.4 Hz, 1H, H3a′′′′); 5.22 (dd, J = 1.5, 10.5 Hz, 1H, H3b′′′′); 5.13 (d, J = 18.3 Hz, 1H, H3a′); 5.08 
(d, J = 9.6 Hz, 1H, H3b′); 4.50 – 4.48 (m, 3H, H1′′′′ and H5); 4.42 – 4.36 (m, 2H, H2 and H8); 3.69 
(s, 3H, OCH3); 3.21 – 3.15 (m, 2H, H3′′); 3.02 (dd, J = 5.7, 13.8 Hz, 1H, ArCHH); 2.82 (dd, J = 
9.0, 14.1 Hz, 1H, ArCHH); 2.60 – 2.41 (m, 2H, H1′); 1.92 (s, 3H, H11); 1.88 – 1.81 (m, 2H, H1′′); 
1.70 – 1.58 (m, 2H, H2′′). 
13
C NMR (CD3OD, 75 MHz): δ 173.9, C4; 173.5, C11; 173.4, C1; 173.2, 
C7; 158.8, ArC4′′′; 158.4, CN3; 134.9, C2′′′′; 134.2, C2′; 131.2, ArC1′′′; 130.3, ArCH2′′′ and 
ArCH6′′′; 117.4, C3′; 116.2, C3′′′′; 115.6, ArCH3′′′ and ArCH5′′′; 69.7, C1′′′′; 56.6, C2; 53.8, C5; 
53.6, C8; 52.8, OCH3; 50.1, C3′′; 36.6, ArCH2; 36.5, C1′; 30.3, C2′′; 23.0, C11; 22.5, C1′′. MS 
(ESI, +ve) m/z 531.1 (100%) [MH
+


























oxoundecanoate hydrochloride (58) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 35 (48 mg, 0.60 mmol) 
to yield 58 (32 mg, 0.060 mmol, 100%) as a highly hygroscopic 
solid; [α]D
22
 +16.0 (c 0.008, MeOH). IR (neat) νmax 1652, 1543, 
1512, 1222, 1181, 1047, 1005, 834, 752. 
1
H NMR (CD3OD, 300 
MHz): δ 7.15 (d, J = 8.4 Hz, 2H, ArH2′′′ and ArH6′′′); 6.86 (d, J = 
8.7 Hz, 2H, ArH3′′′ and ArC5′′′); 6.08 – 6.00 (m, 1H, H2′′′′); 5.78 – 5.70 (m, 1H, H2′); 5.38 (dd, J = 
1.5, 17.4 Hz, 1H, H3a′′′′); 5.23 (dd, J = 1.2, 10.5 Hz, 1H, H3b′′′′); 5.09 (dd, J = 1.2, 16.8 Hz, 1H, 
H3a′); 5.06 (d, J = 10.6 Hz, 1H, H3b′); 4.45 – 4.40 (m, 4H, H2′′′′ and  H2); 4.39 (dd, J = 5.7, 8.1 Hz, 
1H, H5); 4.26 (dd, J = 4.5, 8.7 Hz, 1H, H8); 3.68 (s, 3H, OCH3); 3.07 (t, J = 7.2 Hz, 2H, H3′′); 2.89 
– 2.82 (m, 2H, ArCH2); 2.59 – 2.42 (m, 2H, H1′); 1.95 (s, 3H, H11); 1.75 – 1.59 (m, 2H, H1′′); 1.11 
– 1.08 (m, 2H, H2′′).
 13
C NMR (CD3OD, 75 MHz): δ 173.7, C4; 173.6, C11; 173.4, C1; 172.9, C7; 
158.8, ArC4′′′; 158.4, CN3; 134.8, C2′′′′; 134.3, C2′; 131.2, ArC1′′′; 130.0, ArCH2′′′ and ArCH6′′′; 
118.6, C3′; 117.4, C3′′′′; 115.7, ArCH3′′′ and ArCH5′′′;69.8, C1′′′′; 57.2, C2; 53.8, C5; 53.8, C8; 
52.8, OCH3; 50.1, C3′′; 37.7, ArCH2; 36.5, C1′; 29.7, C2′′; 22.9, C11; 22.3, C1′′. MS (ESI, +ve) m/z 
531.5 (80%) [MH
+
]. HRMS calcd for C26H39N6O6 531.2931, found 531.2936. 
 
5.11.6. Methyl (2R,5S,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-(3-[guanidino]propyl)-4,7,10-
oxoundecanoate hydrochloride (59) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 36 (87 mg, 0.11 mmol) 
to yield 59 (35 mg, 0.062 mmol, 56%) as a highly hygroscopic solid; 
[α]D
22
 +16.0 (c 0.008, MeOH). IR (neat) νmax 1652, 1543, 1512, 1222, 
1181, 1047, 1005, 834, 752. 
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J = 8.5 Hz, 2H, ArH2′′′ and ArH6′′′); 6.83 (d, J = 8.0 Hz, 2H, ArH3′′′ and ArH5′′′); 6.10 – 5.98 (m, 
1H, H2′′′′); 5.84 – 5.70 (m, 1H, H2′); 5.38 (dd, J = 1.5, 17.5 Hz, 1H, H3a′′′′); 5.23 (dd, J = 1.0, 10.5 
Hz, 1H, H3b′′′′); 5.12 (d, J = 17.0 Hz, 1H, H3a′); 5.08 (d, J = 10.5 Hz, 1H, H3b′); 4.50 (d, J = 5.0 Hz, 
2H, H1′′′′); 4.42 – 4.37 (m, 3H, H2, H5 and H8); 3.71 (s, 3H, OCH3); 2.97 (t, J = 7.5 Hz, 2H, H3′′); 
3.02 – 2.85 (m, 2H, ArCH2); 2.63 – 2.45 (m, 2H, H1′); 1.93 (s, 3H, CH3, H11); 1.84 – 1.73 (m, 2H, 
H1′′); 1.63 – 1.60 (m, 2H, H2′′).
 13
C NMR (CD3OD, 75 MHz): δ 173.9, C4; 173.4, C11; 173.1, C1; 
172.9, C7; 158.8, ArC4′′′; 158.4, CN3; 134.8, C2′′′′; 134.1, C2′; 131.1, ArC1′′′; 130.2, ArCH2′′′ and 
ArCH6′′′; 118.9, C3′; 117.2, C3′′′′; 115.6, ArCH3′′′ and ArCH5′′′;69.7, C1′′′′; 56.9, C2; 53.8, C5; 
53.6, C8; 52.8, OCH3; 50.1, C3′′; 37.7, ArCH2; 36.9, C1′; 26.1, C2′′; 22.5, C11; 20.7, C1′′. MS 
(ESI, +ve) m/z 531.1 (85%) [MH
+
]. HRMS calcd for C26H39N6O6 531.2931, found 531.2952. 
 
5.12. Synthesis of Acyclic GuanidineLysine Derivatives (Scheme 7) 
5.12.1. Methyl (2S,5R,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-(4[{N,N-di-tert-
butoxycarbonyl}guanidino]butyl)-4,7,10-trioxoundecanoate (60) 
To a solution of 9 (56 mg, 0.093 mmol) in CH2Cl2 (2 mL) was 
added TFA (2 mL) and the resulting mixture was allowed to stir 
for 3 h. The solvent was concentrated and the intermediate 
trifluoroacetate salt was precipitated by addition of diethyl ether 
and collected as a solid by vacuum filtration. To this solid was 
added N-tert-
butoxycarboxamido(trifluoromethylsulfonylimino)methyl propanamide (65 mg, 0.17 mmol), 
triethylamine (0.2 mL) and CH2Cl2 (2 mL). The resulting solution was allowed to stir for 16 h under 
N2. The solvent was evaporated and the crude product was purified by flash column 
chromatography (15:1, CH2Cl2/ MeOH) to yield the title compound as a 1:1 mixture of epimers (70 
mg, 0.093 mmol, 100%) as an orange/yellow solid. Mp 112-114 °C. 
 1
H NMR (CDCl3, 300 MHz): δ 




























J = 7.6 Hz, 1H, NH); 7.11 – 6.79 (m, 2H, ArH3′′′ and ArH5′′′); 6.72 (d, J = 7.2 Hz, 1H, NH); 6.60 
(d, J = 7.6 Hz, 1H, NH); 6.07 – 5.96 (m, 1H, H2′′′′); 5.71 – 5.61 (m, 1H, H2′); 5.38 (d, J = 17.3 Hz, 
1H, H3a′′′′); 5.26 (d, J = 10.5 Hz, 1H, H3b′′′′); 5.14 – 5.06 (m, 2H, H3′); 4.70 – 4.34 (m, 5H, H2, H5, 
H8 and H2′′′′); 3.74/3.70 (s, 3H, OCH3); 3.32 (d, J = 6.7 Hz, 2H, H4′′); 3.00 – 2.86 (m, 2H, ArCH2); 
2.56 – 2.43 (m, 2H, H1′); 1.97/1.96 (s, 3H, H11); 1.40 – 1.05 (m, 6H, H1′′, H2′′ and H3′′); 1.49 (s, 
18H, 2 x C(CH3)3). 
13
C NMR (CDCl3, 75 MHz): δ 172.1/171.7, C7; 171.4/171.3, C1; 170.9, C4; 
170.7, C10; 163.1, CN3; 157.5/157.4, ArC4′′′; 156.0/155.9, NCO2; 153.0, NCO2; 133.1/133.0, C2′; 
132.1/131.9, C2′′′′; 130.0, ArCH2′′′ and ArCH6′′′; 128.2/128.0, ArC1′′′; 119.1/118.9, C3′; 
117.5/117.3, C3′′′′; 114.8/114.7, ArCH3′′′ and ArCH5′′′; 83.2/83.1, C(CH3)3; 79.5/79.4, C(CH3)3; 
68.7, C1′′′′; 55.4/54.6, C5; 52.9, OCH3; 52.5/52.8, C8; 51.9/51.8, C2; 40.7/40.5, C4′′; 37.2, ArCH2; 
36.3, C1′; 36.1, C1′′; 31.9/31.5, C3′′; 28.6/28.3, C(CH3)3; 22.9/22.7, C11; 22.5, C2′′. MS (ESI, +ve) 
m/z 745.4 (100%) [MH
+




To a solution of 32 (41 mg, 0.081 mmol) in CH2Cl2 (2 mL) was 
added N-tert-
butoxycarboxamido(trifluoromethylsulfonylimino)methyl 
propanamide (35 mg, 0.089 mmol), triethylamine (0.1 mL). The 
resulting solution was allowed to stir for 16 h under N2. The 
solvent was evaporated and the crude product was purified by 
flash column chromatography (15:1, CH2Cl2/ MeOH) to yield the 
title compound as a 1:1 mixture of epimers (45 mg, 0.060 mmol, 74%) as an orange/yellow solid. 
Mp 114-118 °C. 
  1
H NMR (CDCl3, 300 MHz): δ 8.26 (bs, 1H, NH); 7.08 (t, J = 8.4 Hz, 2H, ArH2′′′ 
and ArH6′′′); 6.99 – 6.94 (m, 1H, NH); 6.83 (t, J = 8.4 Hz, 2H, ArH3′′′ and ArH5′′′); 6.73 (d, J = 




























H2′); 5.39 (d, J = 17.3 Hz, 1H, H3a′′′′); 5.26 (d, J = 10.1 Hz, 1H, H3b′′′′); 5.14 – 5.06 (m, 2H, H3′); 
4.70 – 4.33 (m, 5H, H2, H5, H8 and H1′′′′); 3.74/3.71 (s, 3H, OCH3); 3.33 (bs, 2H, H4′′); 3.05 – 
2.88 (m, 2H, H1′); 2.59 – 2.46 (m, 2H, ArCH2); 1.97 (s, 3H, H11); 1.50 – 1.20 (m, 6H, H1′′, H2′′ 
and H3′′);1.49 (s, 18H, C(CH3)3). 
13
C NMR (CDCl3, 75 MHz): δ 171.7/171.6, C7; 171.3/171.2, C1; 
170.9/170.7, C4; 170.6, C10; 163.2/163.1, CN3; 157.5/157.4, ArC4′′′; 156.0, NCO2; 153.1/151.4, 
NCO2; 133.1/133.0, C2′; 132.0/131.9, C2′′′′; 130.1, ArCH2′′′ and ArCH6′′′; 128.2/128.1, ArC1′′′; 
119.2/119.0, C3′; 117.5, C3′′′′; 114.8/114.7, ArCH3′′′ and ArCH5′′′; 83.2/83.1, NCO2; 79.5/79.4, 
NCO2; 68.7, C1′′′′; 55.2/54.5, C5; 53.1/53.0, OCH3; 52.4, C8; 52.4/51.9, C2; 40.7/40.5, C4′′; 37.2, 
ArCH2; 36.1, C1′; 32.0/31.6, C1′′; 28.6/28.3, C(CH3)3; 28.1/27.8, C(CH3)3; 22.9, C11; 22.6, C2′′. 
MS (ESI, +ve) m/z 745.2 (100%) [MH
+
]. HRMS calcd for C37H57N6O10 745.4136, found 745.4105. 
 
5.12.3. Methyl (2S,5R,8S)-2-allyl-9-(4-allyloxybenzyl)-5-(4-[guanidino]butyl)-3,6,9-triaza-4,7,10-
trioxoundecanoate hydrochloride (62) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 60 (71 mg, 0.095 
mmol) to yield 62 (43 mg, 0.074 mmol, 78%) as a yellow 
hygroscopic solid.
 1
H NMR (CD3OD, 300 MHz): δ 8.25 – 8.15 (m, 
2H, NH x 2); 7.15 (d, J = 8.4 Hz, 2H, ArH2′′′ and ArH6′′′); 6.87 
(d, J = 8.4 Hz, 2H, ArH3′′′ and ArH5′′′); 6.10 – 5.96 (m, 1H, 
H2′′′′); 5.80 – 5.66 (m, 1H, H2′); 5.39 (d, J = 17.3 Hz, 1H, H3a′′′′); 5.24 (d, J = 10.5 Hz, 1H, H3b′′′′); 
5.12 (d, J = 6.0 Hz, 1H, H3a′); 5.05 (d, J = 9.9 Hz, 1H, H3b′); 4.52 – 4.37 (m, 4H, H2, H5 and 
H1′′′′); 4.17 (dd, J = 4.0, 8.7 Hz, 1H, H8); 3.72 (s, 3H, OCH3); 3.18 – 2.80 (m, 4H, H1′ and H4′′); 
2.62 – 2.42 (m, 2H, ArCH2); 1.94 (s, 3H, H11); 1.83 – 1.39 (m, 4H, H2′′ and H3′′); 1.05 – 0.97 (m, 
2H, H1′′). 
13
C NMR (CD3OD, 75 MHz): δ 174.3, C4; 174.0, C11; 173.3, C1; 173.2, C7; 159.0, 
ArC4′′′; 158.5, CN3; 134.9, C2′′′′; 134.5, C2′; 131.4, ArC1′′′; 130.4, ArCH2′′′ and ArCH6′′′; 118.6, 






















OCH3; 42.1, C4′′; 37.5, ArCH2; 36.4, C1′; 31.9, C2′′; 29.2, C3′′; 23.6, C11; 22.4, C1′′. MS (ESI, 
+ve) m/z 545.4 (100%) [MH
+
]. HRMS calcd for C27H41N6O6 545.3088, found 545.3073. 
 
5.12.4. Methyl (2S,5S,8S)-2-allyl-9-(4-allyloxyphenyl)-5-(4-[guanidino]butyl)-3,6,9-triaza-4,7,10-
trioxoundecanoate hydrochloride (63) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 61 (40 mg, 0.054 
mmol) to yield 63 (11 mg, 0.019 mmol, 35%) as a highly 
hygroscopic yellow solid.
 1
H NMR (CD3OD, 300 MHz): δ 7.10 
(bs, 2H, ArH2′′′ and ArH6′′′); 6.79 (bs, 2H, ArH3′′′ and ArH5′′′); 
6.10 – 5.90 (m, 1H, H2′′′′); 5.84 – 5.62 (m, 1H, H2′); 5.36 – 4.99 
(m, 4H, H3′′′′ and H3′); 4.45 – 4.10 (m, 5H, H2, H5, H8 and H1′′′′); 3.65 (s, 3H, OCH3); 3.11 – 2.70 
(m, 4H, H1′ and H4′′); 2.49 (bs, 2H, ArCH2); 1.87 (s, 3H, H11); 1.47 – 1.23 (m, 6H, H1′′, H2′′ and 
H3′′). 
13
C NMR (CD3OD, 75 MHz): δ 174.2, C4; 174.1, C11; 173.6, C1; 173.2, C7; 159.4, ArC4′′′; 
158.4, CN3; 134.6, C2′′′′; 134.2, C2′; 131.2, ArC1′′′; 130.3, ArCH2′′′ and ArCH6′′′; 119.6, C3′; 
118.2, C3′′′′; 116.3, ArCH3′′′ and ArCH5′′′; 70.0, C1′′′′; 57.4, C2; 54.4, C5; 53.9, C8; 52.4, OCH3; 
42.2, C4′′; 37.6, ArCH2; 36.6, C1′; 32.5, C2′′; 29.5, C3′′; 23.6, C11; 22.8, C1′′. MS (ESI, +ve) m/z 
545.3 (100%) [MH
+























5.13. Synthesis of Cyclic GuanidineLysine Derivatives (Scheme 8) 
5.13.1.(7S,10S,13S,4E/Z)-13-Acetamido-8,11-diaza-10-(4-[{N,N-di-tert-butoxycarbonyl}guanidino] 
butyl)-7-methoxycarbonyl-2-oxa-9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene (64) 
To a solution of 10 (75 mg, 0.15 mmol) in CH2Cl2 (2 mL) was added 
N-tert-butoxycarboxamido(trifluoromethylsulfonylimino)methyl 
propanamide (115 mg, 0.29 mmol), triethylamine (0.1 mL) and 
CH2Cl2 (2 mL). The resulting solution was allowed to stir for 16 h 
under N2. The solvent was evaporated and the crude product was 
purified by flash column chromatography (15:1, CH2Cl2/MeOH) to 
yield 64 as a 1:1 mixture of epimers (96 mg, 0.13 mmol, 87%) as an orange/yellow solid. Mp 104-
102 °C. 
1
H NMR (CDCl3, 300 MHz): δ 8.28 – 8.24 (m, 1H, NH); 7.14 – 6.71 (m, 4H, ArH ); 6.00 – 
5.50 (m, 2H, H4 and H5); 4.77 – 4.55 (m, 5H, H2, H7, H10 and H13); 3.79/3.78 (s, 3H, OCH3); 
3.34 – 3.23 (m, 2H, H4′); 2.99 – 2.87 (m, 2H, H6); 2.77 – 2.637 (m, 2H, H14); 2.09/2.07 (s, 3H, 
NCOCH3); 1.60 – 1.50 (m, 6H, H1′, H2′ and H3′); 1.49/1.48 (s, 18H, C(CH3)3). 
13
C NMR (CDCl3, 
75 MHz): δ 172.1/171.8, C9; 170.8/170.7, 7-CO; 170.3, 13-NCO; 169.9, C12; 163.6, CN3; 156.7, 1-
ArC1; 156.3/156.2, NCO2; 153.4/153.3, NCO2; 130.4, 1-ArCH2 and 1-ArCH6; 129.9, C4; 128.4, 
C5; 127.6, 1-ArC4; 116.8, 1-ArCH3 and 1-ArCH5; 83.4/83.3, C(CH3)3; 79.5/79.4, C(CH3)3; 66.2, 
C3; 54.8, C13; 53.8, C10; 52.1, OCH3; 41.1, C4′; 33.9, C7; 31.3, C14; 30.0, C6; 29.2, C(CH3)3; 
27.5, C3′; 23.5, 13-NCOCH3; 22.6, C2′. MS ( ESI, +ve) m/z 717.4 (100%) [MH
+
]. HRMS calcd for 

























oxa-9,12-dioxo-1(1,4)phenylenacyclotetradecaphane-4-ene hydrochloride (65) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 64 (86 mg, 0.12 mmol) 
to yield 65 (50 mg, 0.097 mmol, 81%) as a highly hygroscopic yellow 
solid. 
1
H NMR (CD3OD, 500 MHz): δ 10.34 (bs, 1H, NH); 7.55 – 
7.36 (m, 2H, ArH); 7.18 – 7.07 (m, 2H, ArH); 5.97 – 5.80 (m, 2H, H4 
and H5); 4.98 – 4.68 (m, 5H, H2, H7, H10 and H13); 3.65 (s, 3H, 
OCH3); 3.32 – 3.31 (m, 2H, H4′); 3.10 – 3.00 (m, 2H, H6); 2.42 – 2.40 (m, 2H, H14); 2.10 (s, 3H, 
NCOCH3); 2.10 – 2.00 (m, 2H, H3′); 1.90 – 1.80 (m, 2H, H1′); 1.54 – 1.42 (m, 2H, H2′).
 13
C NMR 
(CD3OD, 125 MHz): δ 173.3/173.2, C9; 172.7/173.6, 7-CO; 172.5, 13-NCO; 169.4, C12; 
158.5/158.4, 1-ArC1; 131.4/131.3, 1-ArCH2 and 1-ArCH6; 131.0, C4; 129.3, C5; 129.0, 1-ArC4; 
116.5, 1-ArCH3 and 1-ArCH5; 67.0, C3; 58.2, C7; 57.5, C13; 57.4, C10; 53.9, OCH3; 42.1, C4′; 
33.9, C14; 29.0, C6; 23.5, C3′; 22.7, C1′; 22.5, NCOCH3; 22.5, C2′. MS (ESI, +ve) m/z 517.4 
(100%) [MH
+
]. HRMS calcd for C25H37N6O6 517.2775, found 517.2765. 
 
5.14. Synthesis of Dityrosine Cyclic Peptides (Scheme 9) 
5.14.1. Methyl (2S)-(4-hydroxyphenyl)-2-tert-butoxycarboxamido propanoate (67) 
To a solution of (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid 66 (5.23 g, 
28.9 mmol) in anhydrous MeOH (20 mL) at 0 °C was added dropwise thionyl 
chloride (2 mL). The resulting mixture was allowed to stir for 40 h before the 
solvent was removed by evaporation and the resulting hydrochloride salt was 
dissolved in DMF (15 mL). To this solution was added di-tert-butyl-dicarbonate (9.44 g, 43.3 
mmol) and the reaction mixture was allowed to reach RT whilst stirring. After 16 h the reaction was 
quenched with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined extracts were 


























column chromatography (25 : 1, CH2Cl2/MeOH) to yield the title compound (1.32 g, 4.48 mmol, 




H NMR (CDCl3, 
300 MHz): δ 6.95 (d, J = 8.4 Hz, 2H, ArH2′ and ArH6′); 6.73 (d, J = 8.4 Hz, 2H, ArH3′ and 
ArH5′); 6.51 (bs, 1H, OH); 5.05 (d, J = 8.4 Hz, 1H, NH); 4.57 – 4.50 (m, 1H, H2), 3.71 (s, 3H, 
OCH3); 3.06 – 2.91 (m, 2H, H3); 1.42 (s, 9H, C(CH3)3). 
13
C NMR (CDCl3, 75 MHz): δ 172.5, C1; 
155.2, NCO; 155.1, ArC4′; 130.2, ArCH2′ and ArCH6′; 127.2, ArCH3′ and ArCH5′; 115.4, ArC1′; 
80.2, C(CH3)3; 54.6, C2; 52.3, OCH3; 37.6, C3; 28.3, C(CH3)3. MS (CI, +ve) m/z 196 (100%) [MH
+
 
(less Boc)]. HRMS calcd for C16H22NO5 296.1498, found 296.1503. 
 
5.14.2. Methyl (2S)-3-(4-allyloxyphenyl)-2-tert-butoxycarboxamidopropanoate (68) 
To a solution of 67 (1.30 g, 4.39 mmol) in DMF (15 mL) under an N2 
atmosphere was added K2CO3 (1.21g, 8.79 mmol) and the resulting 
suspension was allowed to stir for 20 min before the addition of allyl bromide 
(0.76 mL, 8.79 mmol). The reaction mixture was allowed to stir for 16 h 
before quenching with water (40 mL) and extracting with EtOAc (3 x 40 mL). The combined 
extracts were washed with water (4 x 40 mL), dried and evaporated to yield the title compound 
(1.21 g, 3.35 mmol, 76%) as a colourless solid, which was identical to that reported.
23
 Mp 142-144 




5.14.3. Methyl (2S)-2-(4-allyloxyphenyl)-2-aminopropanoate hydrochloride (69) 
To a solution of 68 (1.10 g, 3.28 mmol) in CH2Cl2 (5 mL) was added TFA (5 
mL) dropwise. After stirring for 16 h the solvent was removed by evaporation 
and the resulting trifluoroacetate salt was resuspended in methanol (2 mL) and 
treated with 1M HCl/diethyl ether (2 mL). The solution was stirred for 5 min 
before the solvent was evaporated to yield the crude hydrochloride salt. The crude product was 
















100%) as a white solid. Mp 216-220 °C. 
1
H NMR (CD3OD, 300 MHz): δ 7.16 (d, J = 8.4 Hz, 2H, 
ArH2′ and ArH6′); 6.93 (d, J = 8.8 Hz, 2H, ArH3′ and ArH5′); 6.11 – 5.98 (m, 1H, H2′′); 5.38 (dd, 
J = 17.3, 1.7 Hz, 1H, H3a′′); 5.24 (dd, J = 11.8, 1.3 Hz, 1H, H3b′′); 4.55 – 4.53 (m, 2H, H1′′); 4.26 
(t, J = 7.2 Hz 1H, H2); 3.81 (s, 3H, OCH3); 3.23 – 3.06 (m, 2H, H3). 
13
C NMR (CD3OD, 75 MHz): 
δ 170.3, C1; 159.6, ArC4′; 139.6, C2′′; 131.4, ArCH2′and ArCH6′; 127.0, ArC1; 117.4, C3′′; 116.2, 
ArCH3′and ArCH5′; 69.7, C1′′; 55.3, C2; 53.6, OCH3; 36.6, C3. MS (CI, +ve) m/z 236 (90%) 
[MH
+




The title compound was synthesized using the general 
peptide coupling procedure (Procedure B), from 69 (200 mg, 
0.74 mmol) and (2R)-6-tert-butoxycarboxamido-2-[(9H-9-
fluorenylmethyloxy)carboxamido]hexanoic acid (291 mg, 
0.62 mmol) to afford 70 (317 mg, 0.47 mmol, 75%) as a pale 
yellow solid. IR (neat) νmax 11734, 1684, 1653, 1539, 1510, 
1250, 1174, 738. Mp 114-116 °C.
 1
H NMR (CDCl3, 300 
MHz): δ 7.74 (d, J = 7.6 Hz, 2H, ArH1′′′ and ArH8′′′); 7.57 (d, J = 6.3 Hz, 2H, ArH4′′′ and 
ArH5′′′); 7.38 (t, J = 7.2 Hz, 2H, ArH3′′′ and ArH6′′′); 7.28 (t, J = 7.6 Hz, 2H, ArH2′′′ and ArH7′′′); 
6.99 (d, J = 7.6 Hz, 2H, ArH2′ and ArH6′); 6.82 (d, J = 7.2 Hz, 1H, NH); 6.76 (d, J = 8.0 Hz, 2H, 
ArH3′ and ArH5′); 5.99 – 5.95 (m, 1H, H2′′); 5.67 (d, J = 7.2 Hz, 1H, NH); 5.34 (d, J = 16.8 Hz, 
1H, H3a′′); 5.23 (d, J = 10.5 Hz, 1H, H3b′′); 4.81 (d, J = 5.8 Hz, 1H, H2); 4.70 (t, J = 5.9 Hz, 1H, 
H5); 4.38 – 4.34 (m, 3H, OCH2 and OCH2-H9′′′); 4.20 – 4.18 (m, 2H, H1′′); 3.68 (s, 3H, OCH3); 
3.05 – 3.04 (m, 4H, H9 and ArCH2); 1.76 – 1.70 (m, 2H, H6); 1.60 – 1.50 (m, 2H, H7); 1.42 (s, 9H 
C(CH3)3); 1.23 – 1.21 (m, 2H, H8). 
13
C NMR (CDCl3, 75 MHz): δ 171.7, C4; 171.2, C1; 157.4 , 





















133.0, C2′′; 130.0, ArCH2′ and ArCH6′; 127.7, ArCH3′′′ and ArCH6′′′; 127.5, ArCH2′′′ and 
ArCH7′′′; 126.9, ArCH1′′′ and ArCH8′′′; 124.9, ArCH4′′′ and ArCH5′′′; 119.8, ArC1′; 117.4, C3′′; 
114.6, ArCH3′ and ArCH5′; 79.0, C(CH3)3; 68.6, CH2-C9′′′; 67.1, C1′′; 54.6, C5; 53.2, C2; 52.3, 
OCH3; 47.0, C9′′′; 39.9, C9; 37.0, ArCH2; 32.2, C6; 29.6, C8; 28.4, C(CH3)3; 22.3, C7. MS (ESI, 
+ve) m/z 708.4 (100%) [MNa
+




The title compound was synthesized using the general N-Fmoc 
deprotection procedure (Procedure C), from 70 (198 mg, 0.290 
mmol) to yield 71 (131 mg, 0.280 mmol, 97%) as a cream oil.
 1
H 
NMR (CDCl3, 300 MHz): δ 7.63 (d, J = 8.4 Hz, 1H, NH); 7.04 (d, J 
= 8.4 Hz, 2H, ArH2′ and ArH6′); 6.83 (d, J = 8.4 Hz, 2H, ArH3′ and 
ArH5′); 6.11 – 5.98 (m, 1H, H2′′); 5.40 (dd, J = 1.7, 17.3 Hz, 1H, 
H3a′′); 5.28 (dd, J = 1.7, 11.8 Hz, 1H, H3b′′); 4.81 – 4.75 (m, 1H, 
H2); 4.66 (bs, 1H, NH); 4.51 – 4.49 (m, 2H, H1′′); 3.71 (s, 3H, OCH3); 3.32 (dd, J = 4.2, 7.6 Hz, 
1H, H5); 2.60 – 2.54 (m, 4H, ArCH2 and H8); 1.81 – 1.25 (m, 6H, H6, H7 and H8); 1.43 (s, 9H, 
C(CH3)3). 
13
C NMR (CDCl3, 75 MHz): δ 175.0, C4; 172.3, C1; 157.9, NCO2; 156.3, ArC4′; 133.5, 
C2′′; 130.4, ArCH2′ and ArCH6′; 128.5, ArC1′; 118.0, C3′′; 115.0, ArCH3′ and ArCH5′; 79.4, 
C(CH3)3; 69.1, C1′′; 55.3, C2; 54.4, C5; 52.7, OCH3; 40.6, C9; 37.5, ArCH2; 34.8, C6; 30.3, C8; 
28.9, C(CH3)3; 23.1, C7. MS (ESI, +ve) m/z 464.3 (100%) [MH
+
]. HRMS calcd for C24H38N3O6 




















The title compound was synthesized using the general peptide 
coupling procedure (Procedure B), from 71 (220 mg, 0.600 mmol) 
and 14 (132 mg, 0.500 mmol) to yield 72 (130 mg, 0.180 mmol, 
37%) as a white solid. Mp 185-186 °C.
 1
H NMR (CDCl3, 300 
MHz): δ 7.36 (d, J = 7.6 Hz, 2H, NH); 7.08 (d, J = 8.4 Hz, 2H, 
ArH2′ and ArH6′); 7.02 (d, J = 8.4 Hz, 2H, ArH2′′′′ and ArH6′′′′); 
6.82 (d, J = 8.4 Hz, 4H, ArH3′, ArH5′, ArH3′′′′ and ArH5′′′′); 6.63 
(d, J = 7.2 Hz, 1H, NH); 6.10 – 5.94 (m, 2H, H2′′ and H2′′′′′); 5.43 
– 5.24 (m, 4H, H3′′ and H3′′′′′); 4.82 – 4.75 (m, 2H, H2 and H8); 4.62 – 4.58 (m, 1H, H5); 4.91 – 
4.44 (m, 4H, H1′′ and H1′′′′′); 3.67 (s, 3H, OCH3); 3.04 – 2.89 (m, 6H, Ar′-CH2, Ar′′′′-CH2 and 
H4′′′); 1.93 (s, 3H, H11); 1.43 (s, 9H, C(CH3)3); 1.37 – 1.26 (m, 6H, H1′′′, H2′′′ and H3′′′). 
13
C 
NMR (CDCl3, 75 MHz): δ 172.2, C7; 170.8, C4; 170.6, C1; 170.1, C10; 157.4, NCO2; 157.3, 
ArC4′′′′; 155.8, ArC4′; 133.0, C2′′ and C2′′′′′; 130.1, ArCH2′ and ArCH6′; 130.1, ArCH2′′′′ and 
ArCH6′′′′; 128.4, ArC1′′′′; 128.0, ArC1′; 117.5, C3′′ and C3′′′′′; 114.7, ArCH3′ and ArCH5′; 114.6, 
ArCH3′′′′ and ArCH5′′′′; 78.9, C(CH3)3; 68.7, C1′′; 68.7, C1′′′′′; 55.1, C2; 53.3, C5; 52.6, OCH3; 
52.3, C8; 40.1, C4′′′; 37.5, Ar′CH2; 37.2, Ar′′′′CH2; 31.9, C1′′′; 29.7, C3′′′; 28.5, C(CH3)3; 23.0, 
C11; 22.1, C2′′′. MS (ESI, +ve) m/z 709.3 (100%) [MH
+





























trioxoundecanoate hydrochloride (73) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 72 (33 mg, 0.051 
mmol) to yield 73 (18 mg, 0.028 mmol, 55%) as a yellow solid. 
Mp 186-190 °C. 
1
H NMR (CD3OD, 500 MHz): δ 7.50 (bs, 1H, 
NH); 7.41 (bs, 4H, ArH); 7.26 – 7.10 (m, 4H, ArH); 6.46 – 6.30 
(m, 2H, H2′′ and H2′′′′′); 5.80 – 5.64 (m, 4H, H3′′ and H3′′′′′); 4.99 
– 4.70 (m, 6H, H2, H8, H1′′ and H1′′′′′); 4.55 – 4.42 (m, 1H, H5); 3.70 (s, 3H, OCH3); 3.42 – 3.18 
(bs, 6H, H4′′′, Ar′-CH2 and Ar′′′′-CH2); 2.27 (s, 3H, H11); 2.05 – 1.65 (m, 4H, H1′′ and H3′′); 1.33 
(m, 2H, H2′′).
 13
C NMR (CD3OD, 125 MHz): δ 173.9, C7; 173.7, C4; 173.1, C1; 172.0, C10; 158.5, 
ArC4′′′′ and ArC4′; 134.7, C2′′ and C2′′′′′; 131.3, ArCH2′ and ArCH6′; 131.1, ArCH2′′′′ and 
ArCH6′′′′; 130.0, ArC1′′′′; 129.8, ArC1′; 117.8, C3′′; 117.5, C3′′′′′; 115.8, ArCH3′ and ArCH5′; 
115.6, ArCH3′′′′ and ArCH5′′′′; 70.0, C1′′; 69.8, C1′′′′′; 57.2, C2; 55.2, C5; 53.8, OCH3; 52.4, C8; 
40.7, C4′′′; 37.4, Ar′-CH2; 37.1, Ar′′′′-CH2; 31.7, C1′′′; 27.9, C3′′′; 23.2, C11; 22.2, C2′′′. MS (ESI, 
+ve) m/z 609.7 (100%) [MH
+




The title compound was prepared using the general procedure for olefin 
metathesis (Procedure D), from 72 (56 mg, 0.079 mmol) to yield 74 (22 
mg, 0.032 mmol, 41%) as a brown solid. Mp 190-194 °C. 
1
H NMR 
(CDCl3, 300 MHz): δ 7.13 – 6.73 (m, 8H, ArH); 6.02 – 5.83 (m, 2H, H4 
and H5); 5.02 – 4.94 (m, 1H, H10); 4.86 – 4.76 (m, 1H, H16); 4.61 – 
4.50 (m, 4H, H3 and H6); 4.18 – 4.10 (m, 1H, H13); 3.74 (s, 3H, 













































1.97 (s, 3H, NCOCH3); 1.25 (s, 9H, C(CH3)3); 1.93 – 0.88 (m, 6H, H1′, H2′ and H3′).
 13
C NMR 
(CDCl3, 75 MHz): δ 171.8, C12; 170.0, NCOCH3; 169.8, 10-CO; 169.2, C15; 157.3, 1-ArC1; 
157.3, 8-ArC1; 156.1, NCO2; 130.8, 8-ArC4; 130.4, 8-ArCH2 and 8-ArCH6; 130.3, 1-ArCH2 and 
1-ArCH6; 128.7, C4; 128.5, C5; 126.3, 1-ArCH4; 115.1, 8-ArCH3 and 8-ArCH5; 114.7, 1-ArCH3 
and 1-ArCH5; 79.3, C(CH3)3; 68.2, C3; 67.9, C6; 54.8, C16; 52.5, C13; 52.3, OCH3; 52.1, C10; 
39.5, C4′; 38.0, C9; 35.8, C17; 34.9, C1′; 31.9, C3′; 28.5, C(CH3)3; 26.2, 16-NCOCH3; 23.3, C2′. 
MS (ESI, -ve) m/z 725.4 (100%) [MH
+ 
+ formate], 681 (85%) [MH
+
]. HRMS calcd for C36H49N4O9 




The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 74 (22 mg, 0.038 mmol) 
to yield 75 (20 mg, 0.034 mg, 89%) as a yellow solid. Mp >260 °C. 
1
H 
NMR (CD3OD, 300 MHz): δ 8.16 – 8.03 (m, 3H, NH); 7.13 – 7.02 (m, 
4H, ArH); 6.83 – 6.70 (m, 4H, ArH); 6.04 – 5.93 (m, 2H, H4 and H5); 
4.66 (bs, 4H, H3 and H6); 4.60 – 4.50 (m, 1H, H10); 4.42 – 4.36 (m, 
1H, H16); 4.16 – 4.06 (m, 1H, H13); 3.75 – 3.67 (m, 3H, OCH3); 3.09 – 2.73 (m, 6H, H9, H17 and 
H4′); 1.92 (s, 3H, NCOCH3); 1.52 – 1.28 (m, 4H, H1′ and H2′); 0.98 – 0.75 (m, 2H, H3′).
 13
C NMR 
(CD3OD, 75 MHz): δ 171.1, C12; 170.3, NCOCH3; 169.9, 10-CO; 169.4, C15; 157.3, 1-ArC1; 
157.13, 8-ArC1; 130.9, 8-ArC4; 130.5, 8-ArCH2 and 8-ArCH6; 130.1, 1-ArCH2 and 1-ArCH6; 
128.8, C4; 128.4, C5; 126.3, 1-ArCH4; 115.5, 8-ArCH3 and 8-ArCH5; 114.4, 1-ArCH3 and 1-
ArCH5; 68.6, C3; 67.9, C6; 54.8, C16; 52.6, C13; 52.4, OCH3; 52.2, C10; 39.5, C4′; 38.0, C9′; 
35.8, C17; 34.9, C1′; 32.0, C3′; 26.5, 16-NCOCH3; 23.3, C2′. MS (ESI, -ve) m/z 581.6 (100%) 
[MH
+





















5.15. Synthesis of L-Tyrosine Acyclic Dipeptides Hydrochloride Salts (Scheme 10) 
5.15.1. Methyl (2S,5S)-2-(4-allyloxybenzyl)-3-aza-9-(tert-butoxycarboxamido)-5-(9H-9-
fluorenylmethylcarboxamido)-4-oxononanoate (76) 
The title compound was synthesized using the general peptide 
coupling procedure (Procedure B), from 69 (200 mg, 0.74 
mmol) and (2S)-6-tert-butoxycarboxamido-2-[(9H-9-
fluorenylmethyloxy)carboxamido]hexanoic acid (291 mg, 0.62 
mmol) to afford 76 (328 mg, 0.48 mmol, 77%) as a pale 
yellow solid. Mp 52-54 °C.
 1
H NMR (CDCl3, 300 MHz): δ 
7.75 (d, J = 7.5 Hz, 2H, ArH1′′′ and ArH8′′′); 7.59 (d, J = 6.9 
Hz, 2H, ArH4′′′ and ArH5′′′); 7.39 (t, J = 7.5 Hz, 2H, ArH3′′′ and ArH6′′′); 7.30 (dd, J = 1.2, 7.5 
Hz, 2H, ArH2′′′ and ArH7′′′); 6.98 (d, J = 8.4 Hz, 2H, ArH2′ and ArH6′); 6.77 (d, J = 8.7 Hz, 2H, 
ArH3′ and ArH5′); 6.58 (d, J = 7.2 Hz, 1H, NH); 6.02 – 5.92 (m, 1H, H2′′); 5.56 (d, J = 6.9 Hz, 1H, 
NH); 5.35 (dd, J = 1.5, 17.1 Hz, 1H, H3a′′); 5.24 (dd, J = 1.5, 10.8 Hz, 1H, H3b′′); 4.81 (dd, J = 6.0, 
13.8 Hz, 1H, H2); 4.70 (t, J = 5.1 Hz, 1H, H5); 4.43 – 4.35 (m, 4H, H1′′ and OCH2-H9′′′); 4.20 (d, J 
= 7.2 Hz, 2H, H1′′); 3.70 (s, 3H, OCH3); 3.10 – 3.02 (m, 4H, H9 and ArCH2); 1.83 – 1.78 (m, 2H, 
H6); 1.66 – 1.64 (m, 2H, H7); 1.43 (s, 9H C(CH3)3); 1.36 – 1.33 (m, 2H, H8). 
13
C NMR (CDCl3, 75 
MHz): δ 171.7, C4; 171.3, C1; 157.7, NCO2; 156.1, NCO2′′′; 143.7, ArC4′; 141.2, ArC8a′′′ and 
ArC9a′′′; 141.0, ArC4a′′′ and ArC4b′′′; 133.1, C2′′; 130.1, ArCH2′ and ArCH6′; 127.7, ArCH3′′′ 
and ArCH6′′′; 127.5, ArCH2′′′ and ArCH7′′′; 127.0, ArCH1′′′ and ArCH8′′′; 125.0, ArCH4′′′ and 
ArCH5′′′; 119.9, ArC1′; 117.6, C3′′; 114.7, ArCH3′ and ArCH5′; 79.0, C(CH3)3; 68.6, CH2-C9′′′; 
67.1, C1′′; 54.6, C5; 53.3, C2; 52.3, OCH3; 47.0, C9′′′; 39.8, C9; 36.8, ArCH2; 32.0, C6; 29.5, C8; 
28.4, C(CH3)3; 22.2, C7. MS ( ESI, +ve) m/z 686.4 (10%), 708.4 (100%) [MNa
+
]. HRMS calcd for 
























The title compound was synthesized using the general 
peptide coupling procedure (Procedure B), from 69 (200 
mg, 0.74 mmol) and (2R)-2-(9H-9-
fluorenylmethyloxycarboxamido)-8-[(2,2,5,7,8-
pentamethyl-3,4-dihydro-2H-6-
chromenylsulfonyl)guanidino]pentanoic acid (411 mg, 
0.62 mmol) to afford 77 (386 mg, 0.44 mmol, 71%) as a 
pale yellow solid. Mp 86 °C.
 1
H NMR (CDCl3, 300 MHz): δ 7.70 (d, J = 7.5 Hz, 2H, ArH1′′′ and 
ArH8′′′); 7.52 (d, J = 8.7 Hz, 2H, ArH4′′′ and ArH5′′′); 7.33 (dd, J = 7.8, 7.8 Hz, 2H, ArH3′′′ and 
ArH6′′′); 7.23 – 7.16 (m, 2H, ArH2′′′ and ArH7′′′); 6.90 (d, J = 8.1 Hz, 2H, ArH2′ and ArH6′); 6.68 
(d, J = 8.1 Hz, 2H, ArH3′ and ArH5′); 6.32 (bs, 2H, NH); 6.15 (d, J = 8.1 Hz, 1H , NH); 5.97 – 5.84 
(m, 1H, H2′′); 5.29 (d, J = 17.4, 1H, H3a′′); 5.18 (d, J = 10.5 Hz, 1H, H3b′′); 4.71 (dd, J = 7.8, 13.5 
Hz, 1H, H2); 4.31 – 4.24 (m, 5H, H1′′, OCH2-H9′′′ and H5); 4.15 – 4.04 (m, 1H, H9′′′); 3.62 (s, 3H, 
OCH3); 3.23 - 313 (m, 2H, H8); 3.09 – 2.95 (m, 2H, ArCH2); 2.58 (s, 3H, 7′′′′-CH3); 2.58 – 2.52 (m, 
2H, H4′′′′); 2.55 (s, 3H, 5′′′′-CH3); 2.06 (s, 3H, 8′′′′-CH3); 1.71 (t, J = 6.6 Hz, 2H, H3′′′′); 1.62 – 1.57 
(m, 2H, H6); 1.50 – 1.42 (m, 2H, H7); 1.24 (s, 6H, 2 x 2′′′′-CH3).
 13
C NMR (CDCl3, 75 MHz): δ 
172.1, C1; 172.0, C4; 157.4, ArC6′′′′; 156.8, NCO2; 156.2, ArC8a′′′′; 153.6, CN3; 143.7, ArC4′; 
141.2, ArC8a′′′ and ArC9a′′′; 141.0, ArC4a′′′ and ArC4b′′′; 135.4, ArC7′′′′; 134.8, ArC5′′′′; 133.1, 
C2′′; 130.1, ArCH2′ and ArCH6′; 128.7, ArC8′′′′; 128.3, ArCH3′′′ and ArCH6′′′; 127.6, ArCH2′′′ 
and ArCH7′′′; 127.0, ArCH1′′′ and ArCH8′′′; 125.1, ArCH4′′′ and ArCH5′′′; 119.8, ArC1′; 117.9, 
ArC4a′′′′; 117.5, C3′′; 114.6, ArCH3′ and ArCH5′; 73.6, C2′′′′; 68.6, C1′′; 67.2, CH2-C9′′′; 60.4, 
C9′′′; 53.7, C5; 52.3, OCH3; 46.9, C2; 40.3, C8; 36.6, ArCH2; 32.6, C4′′′′; 26.7, 2′′′′-CH3; 21.3, C6; 
21.0, C3′′′′; 18.5, C7; 17.5, 7′′′′-CH3; 14.2, 5′′′′-CH3; 12.0, 8′′′′-CH3. MS (ESI, +ve) m/z 880 
(100%), [MH
+



























5.15.3. Methyl (2S, 5S)-2-(4-allyloxybenzyl)-3-aza-5-(9H-9-fluorenylmethylcarboxamido)-4-oxo-8-
[(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonyl)guanidino]nonanoate (78) 
The title compound was synthesized using the general 
peptide coupling procedure (Procedure B), from 69 (200 
mg, 0.74 mmol) and (2S)-2-(9H-9-
fluorenylmethyloxycarboxamido)-8-[(2,2,5,7,8-
pentamethyl-3,4-dihydro-2H-6-
chromenylsulfonyl)guanidino] pentanoic acid (411 mg, 
0.62 mmol) to afford 78 (460 mg, 0.52 mmol, 84%) as a 
pale yellow solid. Mp 88-90 °C.
 1
H NMR (CDCl3, 300 MHz): δ 7.70 (d, J = 7.8 Hz, 2H, ArH1′′′ and 
ArH8′′′); 7.53 (d, J = 6.6 Hz, 2H, ArH4′′′ and ArH5′′′); 7.40 – 7.25 (m, 2H, ArH3′′′ and ArH6′′′); 
7.21 – 7.18 (m, 2H, ArH2′′′ and ArH7′′′); 6.98 (d, J = 8.1 Hz, 2H, ArH2′ and ArH6′); 6.70 (d, J = 
8.1 Hz, 2H, ArH3′ and ArH5′); 6.34 (bs, 2H, NH); 6.13 (bs, 1H , NH); 5.99 – 5.87 (m, 1H, H2′′); 
5.30 (dd, J = 1.5, 17.1, 1H, H3a′′); 5.19 (d, J = 1.5, 10.5 Hz, 1H, H3b′′); 4.72 – 4.65 (m, 1H, H2); 
4.35 – 4.26 (m, 5H, H1′′, OCH2-H9′′′and H5); 4.15 – 4.06 (m, 1H, H9′′′); 3.60 (s, 3H, OCH3); 3.26 
– 3.16 (m, 2H, H8); 3.04 – 2.88 (m, 2H, ArCH2); 2.58 (s, 3H, 7′′′′-CH3); 2.56 – 2.54 (m, 2H, H4′′′′); 
2.54 (s, 3H, 5′′′′-CH3); 2.07 (s, 3H, 8′′′′-CH3); 1.85 – 1.78 (m, 2H, H6); 1.72 (t, J = 6.9 Hz, 2H, 
H3′′′′); 1.58 – 1.52 (m, 2H, H7); 1.25 (s, 6H, 2 x 2′′′′-CH3). 
13
C NMR (CDCl3, 75 MHz): δ 172.2; 
C1; 172.0, C4; 157.4, ArC6′′′′; 156.8, NCO2; 156.3, ArC8a′′′′; 153.6, CN3; 143.8, ArC4′; 141.1, 
ArC8a′′′ and ArC9a′′′; 141.0, ArC4a′′′ and ArC4b′′′; 135.4, ArC7′′′′; 134.8, ArC5′′′′; 133.2, C2′′; 
130.1, ArCH2′ and ArCH6′; 128.7, ArC8′′′′; 128.2, ArCH3′′′ and ArCH6′′′; 127.6, ArCH2′′′ and 
ArCH7′′′; 127.0, ArCH1′′′ and ArCH8′′′; 125.2, ArCH4′′′ and ArCH5′′′; 119.8, ArC1′; 117.9, 
ArC4a′′′′; 117.5, C3′′; 114.6, ArCH3′ and ArCH5′; 73.6, C2′′′′; 68.5, C1′′; 67.1, CH2-C9′′′; 60.4, 


























21.3, C3′′′′; 18.5, C7; 17.5, 7′′′′-CH3; 14.2, 5′′′′-CH3; 12.0, 8′′′′-CH3. MS (ESI, +ve) m/z 880 (30%), 
902 (100%) [MNa
+
]. HRMS calcd for C48H58N5O9S 880.3955, found 880.3943. 
 
5.15.4. Methyl (2S,5R)-2-(4-allyloxybenzyl)-9-amino-3-aza-5-(9H-9-
fluorenylmethyloxycarboxamido)-4-oxononanoate hydrochloride (79) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 70 (132 mg, 0.19 
mmol) to yield 79 (92 mg, 0.15 mmol, 79%) as a white solid. 
Mp 162-170 °C. 
1
H NMR (CD3OD, 300 MHz): δ 8.02 (d, J = 
8.0 Hz, 1H, NH); 7.79 (d, J = 7.6 Hz, 2H, ArH1′′′ and 
ArH8′′′); 7.64 (t, J = 8.4 Hz, 2H, ArH4′′′ and ArH5′′′); 7.38 
(t, J = 7.2 Hz, 2H, ArH3′′′
 
and ArH6′′′); 7.41 – 7.26 (m, 2H, ArH2′′′ and ArH7′′′); 7.04 (d, J = 8.4 
Hz, 2H, ArH2′
 
and ArH6′); 6.73 (d, J = 8.4 Hz, 2H, ArH3′
 
and ArH5′); 6.00 – 5.87 (m, 1H, H2′′); 
5.28 (d, J = 17.3 Hz, 1H, H3a′′); 5.16 (d, J = 10.5 Hz, 1H, H3b′′); 4.62 (dt, J = 5.0, 8.8 Hz, 1H, H5); 
4.35 – 4.32 (m, 4H, H1′ and OCH2-H9′′′); 4.19 (t, J = 6.7 Hz, 1H, H9′′′); 4.07 (dd, J = 5.1, 8.0 Hz, 
1H, H2); 3.70 (s, 3H, OCH3); 3.14 – 3.07 (m, 2H, H9); 2.93 – 2.82 (m, 2H, ArCH2); 1.63 – 1.53 (m, 
4H, H6 and H7); 1.33 – 1.28 (m, 2H, H8). 
13
C NMR (CD3OD, 75 MHz): δ 174.2, C4; 173.2, C1; 
158.1, NCO2; 145.1, ArC4′; 145.0, ArC8a′′′ and ArC9a′′′; 142.4, ArC4a′′′ and ArC4b′′′; 134.7, C2′′; 
131.1, ArCH2′ and ArCH6′; 129.8, ArCH3′′′ and ArCH6′′′; 128.7, ArCH2′′′ and ArCH7′′′; 128.7, 
ArCH1′′′ and ArCH8′′′; 128.1, ArCH4′′′ and ArCH5′′′; 120.8, ArC1′; 117.3, C3′; 115.6, ArCH3′ and 
ArCH5′; 69.6, CH2-C9′′′; 68.0, C1′′; 56.1, C5; 55.2, C2; 55.1, OCH3; 52.8, C9′′′; 40.5, C9; 37.3, 
ArCH2; 32.6, C6; 28.1, C8; 23.6, C7. MS (ESI, +ve) m/z 586.3 (100%) [MH
+
]. HRMS calcd for 






















fluorenylmethyloxycarboxamido)-4-oxononanoate hydrochloride (80) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 76 (73 mg, 0.106 
mmol) to yield 80 (48 mg, 0.07 mmol, 68%) as a white solid. Mp 
160-168 °C. 
1
H NMR (CD3OD, 300 MHz): δ 7.79 (d, J = 7.2 Hz, 
2H, ArH1′′′ and ArH8′′′); 7.65 (d, J = 7.2 Hz, 2H, ArH4′′′ and 
ArH5′′′); 7.39 (t, J = 7.2 Hz, 2H, ArH3′′′
 
and ArH6′′′); 7.29 (t, J = 
7.2 Hz, 2H, ArH2′′′ and ArH7′′′); 7.07 (d, J = 8.4 Hz, 2H, ArH2′
 
and ArH6′); 6.77 (d, J = 8.4 Hz, 
2H, ArH3′
 
and ArH5′); 6.01 – 5.88 (m, 1H, H2′′); 5.29 (dd, J = 1.2, 18.3 Hz, 1H, H3a′′); 5.16 (dd, J 
= 1.2, 10.5 Hz, 1H, H3b′′); 4.67 – 4.59 (m, 1H, H5); 4.40 – 4.30 (m, 4H, H1′ and OCH2-H9′′′); 4.22 
– 4.18 (m, 1H, H9′′′); 4.12 – 4.07 (m, 1H, H2); 3.67 (s, 3H, OCH3); 3.11 – 3.04 (m, 2H, H9); 2.97 – 
2.87 (m, 2H, ArCH2); 1.73 – 1.60 (m, 4H, H6 and H7); 1.45 – 1.30 (m, 2H, H8). 
13
C NMR 
(CD3OD, 125 MHz): δ 174.4, C4; 173.3, C1; 158.1, NCO2; 145.2, ArC4′; 145.0, ArC8a′′′ and 
ArC9a′′′; 142.4, ArC4a′′′ and ArC4b′′′; 134.7, C2′′; 131.2, ArCH2′ and ArCH6′; 129.8, ArCH3′′′ 
and ArCH6′′′; 128.8, ArCH2′′′ and ArCH7′′′; 128.1, ArCH1′′′ and ArCH8′′′; 126.2, ArCH4′′′ and 
ArCH5′′′; 120.9, ArC1′; 117.4, C3′; 115.6, ArCH3′ and ArCH5′; 69.6, CH2-C9′′′; 68.0, C1′′; 55.9, 
C5; 55.2, C2; 55.1, OCH3; 52.8, C9′′′; 40.4, C9; 37.3, ArCH2; 32.4, C6; 27.9, C8; 23.6, C7. MS 
(ESI, +ve) m/z 586.7 (100%) [MH
+
]. HRMS calcd for C34H40N3O6 586.2917, found 586.2925. 
 
5.15.6. Methyl (2S,5R)-2-(4-allyloxybenzyl)-3-aza-5-(9H-9-fluorenylmethylcarboxamido)-8-
guanidino-4-oxononanoate hydrochloride (81) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 77 (62 mg, 0.068 
mmol) to yield 81 (35 mg, 0.054 mmol, 79%) as a white solid. 
Mp 158-162 °C. 
1






































7.5 Hz, 2H, ArH1′′′ and ArH8′′′); 7.64 (d, J = 8.1 Hz, 2H, ArH4′′′ and ArH5′′′); 7.38 (t, J = 6.9 Hz, 
2H, ArH3′′′ and ArH6′′′); 7.40 – 7.26 (m, 2H, ArH2′′′ and ArH7′′′); 7.04 (d, J = 8.4 Hz, 2H, ArH2′ 
and ArH6′); 6.72 (d, J = 8.4 Hz, 2H, ArH3′ and ArH5′); 6.00 – 5.86 (m, 1H, H2′′); 5.28 (d, J = 17.1, 
1H, H3a′′); 5.16 (d, J = 10.8 Hz, 1H, H3b′′); 4.61 (dd, J = 5.1, 9.0 Hz, 1H, H2); 4.34 – 4.32 (m, 4H, 
H1′′ and OCH2-H9′′′); 4.21 – 4.16 (m, 1H, H5); 4.08 – 4.06 (m, 1H, H9′′′); 3.69 (s, 3H, OCH3); 3.12 
– 3.07 (m, 2H, H8); 2.94 – 2.86 (m, 2H, ArCH2); 1.69 – 1.59 (m, 2H, H6); 1.57 – 1.43 (m, 2H, H7). 
13
C NMR (CD3OD, 75 MHz): δ 172.0, C4; 171.8, C1 156.8, CN3; 156.6, ArC4′; 155.9, NCO2; 
143.8, ArC8a′′′ and ArC9a′′′; 140.8, ArC4a′′′ and ArC4b′′′; 135.5, C2′′; 130.1, ArC1′; 129.6, 
ArCH4′′′ and ArCH5′′′; 127.7, ArCH2′′′ and ArCH7′′′; 127.2, ArCH1′′′ and ArCH8′′′; 125.4, 
ArCH3′′′ and ArCH6′′′; 120.2, ArCH2′ and ArCH6′; 117.3, C3′′; 114.3, ArCH3′ and ArCH5′; 68.0, 
C1′′; 65.8, CH2-C9′′′; 59.3, C9′′′; 54.0, C5; 52.0, OCH3; 46.7, C2; 40.3, C8; 36.1, ArCH2; 29.1, C6; 
24.9, C7. MS (ESI, +ve) m/z 614.6 (100%) [MH
+




guanidino-4-oxononanoate hydrochloride (82) 
The title compound was synthesized using the general N-Boc 
deprotection procedure (Procedure A), from 78 (93 mg, 0.10 
mmol) to yield 82 (54 mg, 0.083 mmol, 83%) as a white 
solid. Mp 170-175 °C. 
1
H NMR (CD3OD, 300 MHz): δ 7.90 
(d, J = 7.2 Hz, 2H, ArH1′′′ and ArH8′′′); 7.75 – 7.70 (m, 2H, 
ArH4′′′ and ArH5′′′); 7.45 – 7.31 (m, 4H, ArH3′′′, ArH6′′′, 
ArH2′′′ and ArH7′′′); 7.14 (d, J = 8.1 Hz, 2H, ArH2′ and ArH6′); 6.82 (d, J = 8.1 Hz, 2H, ArH3′ and 
ArH5′); 6.05 – 5.92 (m, 1H, H2′′); 5.34 (d, J = 17.1, 1H, H3a′′); 5.21 (d, J = 10.8 Hz, 1H, H3b′′); 
4.47 – 4.42 (m, 2H, H2 and H5); 4.29 – 4.24 (m, 4H, H1′′ and OCH2-H9′′′); 4.09 – 4.07 (m, 1H, 




















2H, H6); 1.54 – 1.52 (m, 2H, H7).
 13
C NMR (CD3OD, 75 MHz): δ 171.9, C4; 171.8, C1 157.0, CN3; 
156.6, ArC4′; 155.9, NCO2; 143.9, ArC8a′′′ and ArC9a′′′; 140.7, ArC4a′′′ and ArC4b′′′; 133.8, C2′′; 
130.1, ArC1′; 129.0, ArCH4′′′ and ArCH5′′′; 127.7, ArCH2′′′ and ArCH7′′′; 127.1, ArCH1′′′ and 
ArCH8′′′; 125.4, ArCH3′′′ and ArCH6′′′; 120.1, ArCH2′ and ArCH6′; 117.3, C3′′; 114.4, ArCH3′ 
and ArCH5′; 68.1, C1′′; 65.7, CH2-C9′′′; 59.3, C9′′′; 53.9, C5; 51.8, OCH3; 46.7, C2; 40.3, C8; 35.7, 
ArCH2; 29.0, C6; 25.1, C7. MS ( ESI, +ve) m/z 614.8 (100%) [M
+
]. HRMS calcd for C34H40N5O6 
614.2979, found 614.2972. 
 
5.16. Antibacterial Testing 
Anti-bacterial testing against Staphylococcus aureus ATCC6538P was performed at Avexa Ltd, 
Melbourne, Australia. 
 
Assay procedure: A standardised inoculate for assays was prepared in 1/10 dilution of seed culture. 
To a 96 well microtitre plate was added 50 µL of liquid medium [Mueller-Hinton broth medium 
(MHB) and Mueller-Hinton agar medium (MHA)]. The peptoid compounds were dissolved in a 
50% MeOH/H2O solution for the final concentration of 1 mg/mL. Test solution (50 µL) was added 
into the top row of the plate. A dilution series was continued until it reached the last row of the plate 
the excess was discarded. The plates (2 peptoid samples were tested per plate) were incubated at 37 
°C and shaken at 100 rpm for 18 h. 
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